

Cour d'Appel

Montréal

En appel de la décision rendue le 26 juillet 1991 par
l'honorable juge [REDACTED] par
distribution [REDACTED] are,

Nos: [REDACTED]

LE PROCUREUR GÉNÉRAL DU CANADA
APPELANT-Intimé

c.

RJR-MacDONALD INC.
INTIMÉE-Requérante

-et-

[REDACTED]

LE PROCUREUR GÉNÉRAL DU CANADA
APPELANT-Intimé

c.

IMPERIAL TOBACCO LTD
INTIMÉE-Requérante

-et-

LE PROCUREUR GÉNÉRAL DU QUÉBEC
MIS EN CAUSE-Mis en cause

DOSSIER CONJOINT
Volume XXXIX: pages 7398 à 7574
(Dépositions)

4, rue Notre-Dame Est
Bureau 100
Montréal, Qc H2Y 1B7

Themis Multifactum INC.

Téléphone: (514) 866-3565
Télécopieur: (514) 866-4861

Montréal

Tél.: (514) 866-6674

Tél.: (613) 996-4425

Tél.: (416) 973-0927

Tél.: (514) 283-4040

Tél.: (514) 954-3147

Tél.: (416) 867-3076

Télécopieur (b14) 866-4861

Cour d'Appel

Montréal

MACKENZIE, GERVAIS
(Me Georges R. Thibaut) *Procureurs de l'intimée*
RJR-MacDonald Inc.
770, rue Sherbrooke ouest
Bureau 1300
Montréal (Québec)
H3A 1G1
Tél.: (514) 842-9831

OGILVY RENAULT
(Me Simon V. Potter)
(Me Pierre Bienvenu)
Procureurs de l'intimée
Imperial Tobacco Ltd
1981, avenue McGill College
Bureau 1100
Montréal (Québec)
H3A 3C1
Tél.: (514) 847-4747

OSLER, HOSKIN & HARCOURT
(Lyndon A.J. Barnes, Esq.)
Procureurs de l'intimée
Imperial Tobacco Ltd
1, First Canadian Place
Box 50
Toronto (Ontario)
M5X 1B8
Tél.: (416) 362-2111

BERNARD, ROY & ASSOCIÉS
(Me Jean-Yves Bernard)
Procureurs du Mis en cause
Palais de Justice
1, rue Notre-Dame est
Bureau 8.00
Montréal (Québec)
H2Y 1B6
Tél.: (514) 393-2336

4, Notre-Dame Street East
Suite 100
Montreal, Qc H2Y 1B7

Themis Multifactum INC.

Phone: (514) 866-3565
Fax: (514) 866-4861

Cour d'Appel

Montréal

En appel de la décision rendue le 26 juillet 1991 par
l'honorable [REDACTED] par
distribution [REDACTED]

Nos: [REDACTED]

LE PROCUREUR GÉNÉRAL DU CANADA
APPELANT-Intimé

c.

RJR-MacDONALD INC.
INTIMÉE-Requérante

-et-

[REDACTED]

LE PROCUREUR GÉNÉRAL DU CANADA
APPELANT-Intimé

c.

IMPERIAL TOBACCO LTD
INTIMÉE-Requérante

-et-

LE PROCUREUR GÉNÉRAL DU QUÉBEC
MIS EN CAUSE-Mis en cause

DOSSIER CONJOINT
Volume XXXIX: pages 7398 à 7574
(Dépositions)

4, rue Notre-Dame Est
Bureau 100
Montréal, Qc H2Y 1B7

Chemix Multifactum INC.

Téléphone: (514) 866-3565
Télécopieur: (514) 866-4861

Cour d'Appel

Montreal

BAKER, NUDLEMAN & LAMONTAGNE

(Me Roger E. Baker, c.r.)

Procureurs de l'Appelant

1155, boul. René-Lévesque ouest

Bureau 2720

Montréal (Québec)

H3B 2K8

Tél.: (514) 866-6674

Me JAMES MABBUTT, c.r.

Procureur de l'Appelant

Tour Est

140, rue O'Connor

17e étage

Ottawa (Ontario)

K1A 0G5

Tél.: (613) 996-4425

PAUL EVRAIRE, Esq.

Procureur de l'Appelant

2, First Canadian Place

Bureau 3400

Exchange Tower, Box 36

Toronto (Ontario)

M5X 1K6

Tél.: (416) 973-0927

Me CLAUDE JOYAL

Procureur de l'Appelant

Ministère de la Justice

du Canada

Complexe Guy-Favreau

200, boul. René-Lévesque ouest

Tour est, 9e étage

Montréal (Québec)

H2Z 1X4

Tél.: (514) 283-4040

McMASTER, MEIGHEN

(Me Colin K. Irving)

Procureurs de l'intimée

RJR-MacDonald Inc.

630, boul. René-Lévesque ouest

Bureau 700

Montréal (Québec)

H3B 4H7

Tél.: (514) 954-3147

LERNER & ASSOCIÉS

(Me Earl A. Cherniak, c.r.)

Procureurs de l'intimée

RJR-MacDonald Inc.

Scotia Plaza

40, rue King ouest

19e étage, Box 210

Toronto (Ontario)

M5H 3Y2

Tél.: (416) 867-3076

4, rue Notre-Dame Est

Bureau 160

Montréal (Québec) H2Y 1B7

Chemis Multifactum

Téléphone (514) 866-3565

Télexcopieur (514) 866-4861

Montréal

TABLE DES MATIÈRES

Vol. Page

Le 13 mars 1990

PREUVE DE L'INTIMÉ À L'ENQUÊTE (SUITE)

DONALD T. WIGLE (Suite)	Contre-int. par		
Vol. 45 - pp. 6942 à 7030	Me Cherniak	XXXIX	7398
	Contre-int. par		
Vol. 45 - pp. 7030 à 7094	Me Potter	XXXIX	7493
	Ré-int. par		
Vol. 45 - pp. 7095 à 7111	Me Evraire	XXXIX	7558

*

*

*

CANADA
PROVINCE DE QUÉBEC
DISTRICT DE MONTRÉAL

COUR SUPÉRIEURE

SOUS LA PRÉSIDENTE DE L'HONORABLE JUGE JEAN-JUDE CHABOT, J.C.S.

No: 500-05-009755-883

No: 500-05-009760-883

RJR-MACDONALD INC.
Requérante

IMPERIAL TOBACCO LIMITÉE
Requérante

c.

c.

**LE PROCUREUR GÉNÉRAL DU
CANADA**
Intimé

**LE PROCUREUR GÉNÉRAL DU
CANADA**
Intimé

13 mars 1990 - Vol. 45

COMPARUTIONS :

Pour la requérante
RJR-MACDONALD INC.

Pour la requérante
IMPERIAL TOBACCO LIMITÉE

M^{re} COLIN K. IRVING,
M^{re} GEORGES R. THIBAUDEAU,
EARL A. CHERNIAK, Q.C.,
M^{re} MICHEL A. PINSONNAULT,
Avocats

M^{re} SIMON V. POTTER,
M^{re} PIERRE BIENVENU,
LYNDON A.J. BARNES, ESQ.,
M^{re} GREGORY BORDAN
Avocats

MACKENZIE GERVAIS
Procureurs

Ogilvy, Renault
Procureurs

Pour l'intimé
LE PROCUREUR GÉNÉRAL DU CANADA

M^{re} ROGER E. BAKER, Q.C.,
M^{re} CLAUDE JOYAL,
PAUL EVRAIRE, ESQ.,
Avocats

CÔTÉ & OUELLET
Procureurs

6936

I N D E X

	<u>PAGES</u>
Proof of Respondent (Contd)	
DONALD T. WIGLE	
Cross-Examination (Me Cherniak).....	6942
Cross-Examination (Me Potter).....	7030
Re-Examination.....	7095

6937

LIST OF EXHIBITS

		<u>PAGES</u>
RJR-161	Document: "Premature Mortality Attributable to Smoking and Hazardous Drinking in Canada", Volume 1, Summary, by B.L. Ouellet, J.-M. Romeder and J.M. Lance, November 1977	6953
RJR-162	Letter from the Canadian Medical Association Journal to Mr. Neil E. Collishaw, signed by Bruce Squires for Peter P. Morgan, dated November 5, 1986	6965
RJR-163	Letter from the Canadian Journal of Public Health, Revue Canadienne de Santé Publique, plus comments, to Mr. Neil Collishaw, signed J. M. Last, m.d., dated May 13, 1987	6978
RJR-164	Draft: "Mortality Attributable to cigarette smoking in Canada: An Overview of Current Risk Estimates", prepared by Dr. R.T. Burnett, Mr. Neil E. Collishaw, Dr. D. Krewski, Dr. Y. Mao, Dr. D.T. Wigle for Mr. R. Hickman, Dr. B. Liston, February 11, 1988	6996
ITL-35	From Donald T. Wigle, Article appearing in Chronic Disease Canada in 1986, June 1986, Health Status Indicators	7079
AG-186	En liasse, letter of July 6, 1987 and Appendix	7107

6938

LIST OF OBJECTIONS

	<u>Pages</u>
1. Objection.....	6948
2. Objection.....	6981
3. Objection.....	7096
4. Objection.....	7101

6939

LIST OF UNDERTAKINGSPAGES

1. Faire identifier AG-186 par le témoin
Neil Collishaw

7108

In the year of Our Lord nineteen hundred and ninety (1990),
on this thirteenth (13th) day of the month of March,
PERSONALLY CAME AND APPEARED:

5 Me EARL A. CHERNIAK, Q.C.:

For RJR-Macdonald, Earl Cherniak and Michel
Pinsonneault.

Me SIMON V. POTTER:

For Imperial, Simon Potter. My Lord, I wish to
10 apologize to the Court for being late this morning.

THE COURT:

No problem. I was on the phone with my secretary when
your secretary called, so that's...

Me POTTER:

15 So we both had an emergency. Thank you.

THE COURT:

I didn't have a...

Me PAUL EVRAIRE:

On time as always, are the solicitors for the Attorney
20 General of Canada, maîtres Baker, Williams, Joyal and
Evraire.

Me CHERNIAK:

Ah yes, Mr. ...

THE CLERK:

25 Just a moment, please. We must replace RJR-154.

Me CHERNIAK:

Yes, I'm going to do that next.

In the year of Our Lord nineteen hundred and ninety (1990),
on this thirteenth (13th) day of the month of March,
PERSONALLY CAME AND APPEARED:

5 DONALD T. WIGLE, forty-seven (47) years of age, residing at
[DELETED]

WHO, having made a solemn declaration, doth depose and say as
10 follows:

Me CHERNIAK:

My Lord, I want to replace the exhibit yesterday that
was filed with a missing page. I now have another
15 article that has all the pages.

THE COURT:

Which one was that?

THE CLERK:

154. RJR-154. J'ai l'ancien ici.

20 THE COURT:

Ah. Toujours aussi efficace, comme d'habitude.

CROSS-EXAMINATION BY Me EARL A. CHERNIAK (CONT),

On behalf of Petitioner, RJR-Macdonald Inc.:

25 Q- Dr. Wigle, have you got a copy of RJR-160 in front of

you. That was the nineteen -- January, nineteen
eighty-six (1986) estimate of mortality done by
Collishaw, Tostowaryk and you, which was the first time
you became involved in this process. Now, could you
5 just turn to page eight (8), and if we look at the
bottom of page eight (8) we see that the paper seems to
be dealing with the estimated number -- I'm looking
about five (5) lines from the bottom -- column 5, the
product of columns 3 and 4, gives the estimated number
10 of deaths attributable to smoking in each age and sex
group.

Now, for some reason we don't have the actual table
attached to this document, but I think we can find out
what it says. These values are then summed to yield an
15 age/sex adjusted estimate of thirty-three thousand six
hundred and three (33,603) deaths attributable to
tobacco use in Canada in nineteen eighty-three (1983) or
twenty-six percent (26%) of all deaths among persons
aged thirty-five (35) to eighty-four (84). Do you see
20 that?

A- Yes.

Q- Now, would you look at RJR-159, which is the published
version in nineteen eighty-eight (1988) of the paper,
and if you look at page one sixty-eight (168), Table 2,
25 and we look at the total number of deaths for nineteen

eighty-three (1983), which is at the bottom of the first column of column -- of number -- of the group of columns numbered as 5, we get the same number: thirty-three thousand six hundred and three (33,603) for nineteen eighty-three (1983) deaths.

A- Yes.

Q- So would it be fair to say that the -- the method, at least the nineteen eighty-five (1985) study that's dated January, nineteen eighty-six (1986), that had your name on it for the first time, is in fact the predecessor and uses the same numbers for nineteen eighty-three (1983) as the final study published in the Canadian Journal of Public Health?

A- It would appear to be a predecessor. I'm not sure whether it was the penultimate or where it fits, but it does obviously appear to be a predecessor.

Q- Right. But the fact is that the nineteen eighty-three (1983) figures are precisely the same, right to the number, thirty-three thousand six hundred and three (33,603).

A- Yes.

Q- And, of course, you went on in the final version to use the same method for the nineteen eighty-five (1985) total mortality for Canadians?

A- Yes.

Q- And that hadn't been done by January of nineteen eighty-six (1986) when RJR-160 was actually created; am I correct?

A- Yes.

5 Q- And as we saw yesterday, the two (2) previous papers by Collishaw and Tostowaryk, which were June, nineteen eighty-four (1984) and it looks like some time in nineteen eighty-three (1983) respectively for RJR-A -- I'm sorry, RJR-D and C, they came to significantly lower
10 death figures, around twenty-four thousand (24,000) or so for nineteen eighty-two (1982), twenty-one thousand nine forty-three (21,943) for nineteen eighty-one (1981) and twenty-one thousand seven hundred (21,700) for nineteen sixty-seven (1967); am I correct?

15 A- Yes.

Q- You've had a chance to read them now, have you not?

A- I didn't read these overnight. I left them in the car.

Q- You didn't read these overnight, I see.

And I suggest to you that those two (2) earlier
20 studies by Tostowaryk and Collishaw used precisely the same method. They used the Godley -- the Godley relative risk figures rather than the Hammond relative risk figures which -- because the Hammond relative risk figures were considered to be too low, so they used the
25 Godley figures and they used the same -- the same factor

for proportion of deaths attributable to tobacco use in Canada that was used in the nineteen eighty-five (1985) paper, RJR-160. The same method was used? Am I not correct?

5 A- The same general approach was used. But I thought I saw yesterday the fact that they used the Hammond relative risk in one of the papers.

Q- No, no, let's look at them. I suggest to you they used the Godley relative risk in both papers. It's certainly
10 in the later paper, but I suggest in both papers.

A- Table 1 in the earlier paper would appear to use the Hammond estimates, yes.

Q- Yes, but there were two (2) -- but there were two (2) approaches used in each study.

15 A- They are different though. The later paper uses Godley's relative risk, which are higher for women in particular. The earlier paper uses Hammond's estimates which are from the late fifties (50s), early sixties (60s) and they're substantially lower for women.

20 Q- The RJR-C which is the June, nineteen eighty-four (1984) study that we've used all the figures from nineteen sixty-seven (1967) to nineteen eighty-two (1982), and it comes up with about twenty-four thousand (24,000) total deaths in Canada for nineteen eighty-two (1982), used
25 the Godley study, didn't it?

A- It used the Godley study and came to lower estimates for unexplained reasons.

Q- Yes. And the next year when you got into the picture, the total number increased by just about ten thousand (10,000) using the same approach. That's a fact, isn't it?

A- Well, when I became involved, I introduced the method one (1) which is based on the Canadian data.

Q- Yes.

10 A- And this produced an estimate of about thirty-five thousand (35,000).

Q- Yes.

A- The published version of the paper has all the data to verify that. When you apply the Godley relative risk you get a very similar estimate.

15 Q- But using the Godley figures, using the approach that is used in Table 2 in a published article, when Tostowaryk and Collishaw used it without your help, they came to about twenty-four thousand (24,000) deaths per year.

20 A- They must have made a mistake.

Q- They must have made a mistake, yes.

All right. Now, of course, if we look at the earlier papers and we apply the same analysis to them to find out how many of those excess deaths were over --

25 were people over the age of sixty-five (65) or age of

seventy (70), we'd probably, if we analyzed the figures, find the same factors: fifty percent (50%) of the deaths, approximately, were over the age of seventy (70). People over the age of seventy (70) and about two-thirds over the age of sixty-five (65).

Me EVRAIRE:

Well, objection...

Me CHERNIAK:

Q- As we found when we went through the analysis of your paper yesterday.

Me EVRAIRE:

My Lord, given the last answer by the witness that he feels that the authors of the earlier papers must have made a mistake, it's my view that's exactly as if he'd said he doesn't consider those papers authoritative. On that basis, it's my submission that my friend should not continue to examine on those earlier papers, especially given that the witness has only leafed through them and said he hasn't carefully considered them in any event.

THE COURT:

First of all, that's not the question. And second of all, it's overruled. You're dealing with the RJR-159 figures? It's easy to calculate.

Me CHERNIAK:

I'm dealing with RJR-159 figures which I went through

yesterday and which we demonstrated by just looking at them, a simple process of addition.

THE COURT:

Yes, just add up the numbers and we'll get the answer.

5 Me CHERNIAK:

Just add up the numbers. And I'm, without taking the time to do it, I'm suggesting to the witness that ...

THE COURT:

Well, we'll take the time to do it. We'll do it.

10 Me CHERNIAK:

Well, the problem is that, with respect to one of them, one of them at least, the table...

THE COURT:

15 No, you're talking about his estimate in the public papers. If you look at the numbers in the public papers.

Me CHERNIAK:

20 Oh, I thought we did that yesterday, sir, and it showed that almost exactly fifty percent (50%) of the deaths were over aged -- seventy (70) and over. And if you took the other -- took the deaths over sixty-five (65), I think we came to the conclusion it was about sixty-five percent (65%). I can do that again, sir, if you like. I thought we did that in the evidence
25 yesterday. I think what the evidence shows, because I

added up these figures myself yesterday...

Me POTTER:

My Lord, in nineteen eighty-three (1983), it's
forty-eight point five seven percent (48.57%) and in
5 nineteen eighty-five (1985), it's fifty point three
three (50.33).

THE COURT:

Eighty-three ('83) is what? I'm sorry.

Me POTTER:

10 Eighty-three ('83) is forty-eight point five seven
percent (48.57%), seventy (70) and over, and eighty-five
('85) is fifty point three three percent (50.33%).

THE COURT:

Okay.

15 Me CHERNIAK:

Yes, and the figures for over sixty-five (65) come out
for -- for age -- for nineteen eighty-five (1985), come
out to sixty-three point two percent (63.2%) of the
deaths of people sixty-five (65) years and over. It's a
20 total of the -- the total of the deaths, the thirty-five
thousand some -- thirty-five thousand one hundred and
thirty-one (35,131) deaths in nineteen eighty-five
(1985); twenty-two thousand two hundred and four
(22,204) of those deaths are people aged sixty-five (65)
25 or over.

Q- Now, Dr. Wigle, are you aware of a paper that was prepared in the Department of Health and Welfare by persons named Ouellet, Romeder and Lance?

A- I'm aware they did some work on tobacco-related mortality in the seventies (70s).

Q- They did a paper called "Premature mortality attributable to smoking and hazardous drinking in Canada". Are you aware of that paper?

A- I recall a paper -- that sounds like the paper I remember.

Q- Yes, because on the examination for discovery -- I'm sorry, at the trial in -- yes, at the trial, when Mr. Collishaw was giving evidence -- and we find what I'm going to read, My Lord, at Volume XXII, page thirty-three fifty-two (3352) -- Mr. Collishaw was asked this at line 15:

"If we turn the page to page two (2), Mr. Liston draws the addressee's attention to a paper entitled "Premature Mortality Attributable to Smoking and Hazardous Drinking in Canada" prepared some time ago in the Long-Range Health Planning Branch, which shows the relative importance of risk factors such as alcohol and tobacco and how they can be quantified."

3/0127

He goes on to say -- and what follows now, My Lord, is a quote from Mr. Liston:

"Were this sort of analysis extended to other major risk factors such as physical activity, nutrition, stress and hypertension, the information thus obtained would be useful in developing priorities policies programs that address these risk factors."

And then Mr. Collishaw is asked this question:

"Can you confirm, Mr. Collishaw, that these other major risk factors were known to your department throughout the nineteen eighties (1980), that there are other major risk factors?"

A: Yes, there are. In fact, I worked in the Long-Range Health Planning Branch at the time this document was prepared, and while I'm not an author of the document, I'm quite familiar with it and from that document and others that were prepared at that time, it was quite clear to us that by any measure tobacco use was the most serious of all health hazards and caused more mortalities than all the others combined."

So, Mr. Collishaw indicated that he was aware of such a

paper. I'd like to show you a copy of the paper that Mr. Collishaw was referring to and ask if you -- you can now recognize it as -- as something that you know about?

A- I'm not sure I've seen this version of the -- of the work that's reported, but I've seen something similar to this.

Q- Yes. Was it actually published?

A- There was the working report, as I recall, was published just as a working report. I think it had an orange cover and just said something to the effect that it was a working report or a working document or some such.

Q- Certainly this was known to at least one (1) of the authors of this -- of the report. It was known to Collishaw.

A- I'm also aware that there was this type of work done earlier.

Q- All right. I'm going to tender this, then, as the next -- as the next RJR exhibit, My Lord. We'll give that what number, sir?

THE CLERK:

RJR-161.

Me CHERNIAK:

161?

THE CLERK:

161.

Me CHERNIAK:

Q- Now, just looking at this, sir, Dr. Wigle, we see that the heading is "Premature Mortality Attributable to Smoking and Hazardous Drinking in Canada, Volume 1, Summary". Now, would you look, please, at page four (4)? Perhaps, before I ask you any questions on page four (4), tell us who Ouellet, Romeder and Lance are or were.

A- Barbara Ouellet and Jean-Marie Romeder I know and they were working in Long-Range Planning. I don't know this person, J. M. Lance.

Q- All right. What was their position? What is their background? What is their qualifications?

A- Romeder is a sociologist, I believe. I'm not sure what Ouellet's background is.

Q- Now, let's look at page four (4). Do you see the heading -- now, look at heading 2.3 on page four (4), "Premature mortality", and the authors say this:

"It has been decided to restrict this report to the premature mortality occurring between ages 1 and 70."

It's page four (4), My Lord.

THE COURT:

Right.

Me CHERNIAK:

Item 2.3.

Q- And then, in the next paragraph, the authors go on to say why they did that:

5 "Deaths which occur after age 70 or 80 cannot be considered as preventable as earlier deaths since many of them result from causes largely associated with unknown factors related to aging. From the point of view of the priority
10 for major health problems, it is more important at older ages to reduce disability rather than death. This is well put into perspective by Sir Richard Doll, who said: 'I would therefore rather aim to reduce mortality
15 at young ages and to relieve disability at older ages.'"

The point is for the purposes of this departmental study in nineteen seventy-seven (1977), the researchers did not think it appropriate to use mortality after age
20 seventy (70). I take it that you didn't -- you and your colleagues didn't -- didn't use the same restriction for the same reasons, did you?

4/0126 A- We did not use the same restriction because life expectancy in Canada has increased by several years
25 since the time of this report. The average life

expectancy of Canadians now is seventy-five (75). At the time of this report, it was seventy (70).

Q- You say that there is a difference of five (5) years between age in nineteen seventy-seven (1977) and nineteen eighty-five (1985)?

A- The seventy-seven ('77) report would not have had seventy-seven ('77) mortality data. It probably had...

Q- No, of course not. It would have had the -- it would be based on the Canada Census of nineteen seventy (1970) and the mortality basis that you would have had would have been based on the Canada Census of nineteen eighty (1980).

A- Well, I know that the...

Q- You're not suggesting that there was a five (5) year difference in the life expectancy of Canadians between nineteen seventy (1970) and nineteen eighty (1980), are you?

A- Well, the current average life expectancy of Canadians as of nineteen eighty-six (1986) was seventy-five (75).

Q- The point is, Dr. Wigle, that the fact is that deaths which occur between ages seventy (70) -- or after age seventy (70) or after age eighty (80), as these authors indicate, in fact are largely associated -- or many of them are, as the authors say here, largely associated with unknown factors related to aging. It's a fact of

life, everybody dies from something, don't they?

A- Everyone dies of something, but I don't agree with the statement that the deaths among people in their seventies (70s) are largely due to unknown factors.

5 Q- Any rate, from -- with your study, you've included -- with the study that you did in nineteen eighty -- that you became involved in in nineteen eighty-five (1985), ultimately published in nineteen eighty-eight (1988), you included the -- as fifty percent (50%) of the total
10 of the deaths that was thought to be considered important, the deaths after age seventy (70), which other people in your department in nineteen seventy-seven (1977) had said in this report should not be included in a very similar study -- wider, because it
15 included alcohol as well as tobacco -- because deaths over age seventy (70), many of them result from causes largely associated with unknown factors? You didn't take that into account at all, did you?

A- In our report, there were two (2) methods. The second
20 method did include deaths up to age eighty-four (84), of which about fifty percent (50%) of the deaths were over age seventy (70). The first method only takes the deaths up to age seventy-nine (79), so that if you wanted to exclude deaths above the average life
25 expectancy, you would only exclude the deaths between

the ages of, say, seventy-five (75) and seventy-nine (79), which would be much less than fifty percent (50%).

Q- Dr. Wigle, you didn't even put in a reservation in a footnote or in any part of the article itself about the dangers or the problems associated with using deaths over age seventy (70), did you?

A- The...

Q- Did you? Can you just answer the question? I mean, give your explanation after. Did you? Is there anything that we'll find in either the nineteen eighty-six (1986) article or the ultimate published version that refers to the problem identified in your own department with using deaths over age seventy (70)?

A- My Lord, this is not a question that can be answered yes or no, because...

THE COURT:

Q- Yes, it can.

A- ... there is a problem -- well, there is, My Lord, the -- it's alleged that there is a problem considering deaths over the age seventy (70) as being preventable. I don't accept that, so I cannot say I ignore the problem that existed, because it did not exist. It's a very arbitrary decision to say that deaths over the age of seventy (70) are not worth looking at. I'm not sure that people in that age range would agree. The fact is

that many people are very healthy in their seventies (70s) and there has certainly been studies in recent years showing that even people over age sixty-five (65) who quit smoking do have reduced mortality, so that I just cannot accept that we ignored a problem which exists, because I don't believe it does exist.

Q- So the answer is: no, you did not put any reservations with the explanations that you have given because you didn't feel there was a need for reservations to be made. But there was no -- no reservations, is that the answer, and the explanation is that you don't believe you needed any reservation?

A- Yes.

Me CHERNIAK:

Q- So what you're saying is that you considered the caution that is expressed by Ouellet et al with respect to the use of deaths after age seventy (70) and rejected it. Is that what you're telling us?

A- I'm...

Q- Or you're not -- didn't consider it at all?

A- No, I'm not stating that.

Q- Well, tell us! Did you not consider it all? Did you totally ignore it or did you consider it and say: Ouellet et al and people who think that way are wrong and we're not going to use it, because we know Collishaw

knew about this study. Maybe you didn't, but Collishaw did and he's the lead author here.

A- Well, the simple situation is that there is no agreement as to -- at what age life becomes less valuable and that diseases become less preventable.

Q- We're not talking about value of life, we're talking about whether or not it is appropriate, when trying to determine how many deaths in Canada are attributable to a particular factor, in this case tobacco, you should or should not go as high as age seventy (70) or age eighty (80) and just include those deaths as being exactly as valuable in the study. I don't mean valuable in terms of life, I mean as valuable in making the point of the study, as deaths at an earlier age. All I want to know is: did you give no thought to it at all, you and Wigle and Tostowaryk when you were sitting around your table discussing what was going to go into this study, or did you consider what Ouellet and others like them had said and say: we don't think we should accept that caution. We'll just use the older ages. Which was it?

A- The -- in the estimate that I did, which was method one (1), we chose seventy-nine (79) as the upper age limit because it is within the range of life expectancies for Canadian men and women. Canadian women now have a life expectancy very close to eighty (80). The other factor

we considered was that at some point it does become less meaningful to talk about prevention. For example, I don't think anyone would talk about preventing deaths over the age of one hundred (100). People might not agree with preventing deaths over the age of ninety (90) as being a terribly practical goal. But as you come down, it becomes less clear where you should draw the line. Seventy-five (75), seventy-nine (79) seems an appropriate age range based -- not because life is less valuable thereafter or that deaths are less preventable, it's a more realistic goal to set that we should be able to prevent premature deaths up to age eighty (80) without going to extreme measures.

Q- Now, Dr. Wigle, having made that speech would you now come back to my question, because you haven't answered it.

My question is: did you and Wigle -- did you and Collishaw and Tostowaryk consider not using deaths over age seventy (70) when you were preparing the nineteen eighty-six (1986) paper which ultimately became the nineteen eighty-eight (1988) published paper or did you not? That's my question. Either you did or you didn't.

A- My Lord, I don't believe I can answer the question any better than I already have because we did not approach this in a simplistic way with preconceived notions.

Q- So the answer is...

THE COURT:

So the answer is: no?

Me CHERNIAK:

5 Q- Would you answer it? I think the answer is...

A- The answer is not exactly no, because it's not that we did not -- if I say: no, it means that we did not consider excluding deaths at a lower age limit.

THE COURT:

10 Well, that's the question: did you or did you not consider. That's the question. It's either yes or no or yes, because or no, because, but I mean it's either yes or no.

A- We considered -- for method one (1) we considered where
15 to draw the line, but we didn't start with seventy (70) as a benchmark because -- just because Ouellet et al state that in that report doesn't mean that it's accepted by the department or the country at large.

Me CHERNIAK:

20 Q- Well, let's move on.

Now, we talked about peer review. One of the things that -- one that in -- in the scientific endeavors, as I understand it, people prepare papers like you and Collishaw and Tostowaryk did that became
25 RJR-160 and ultimately they're submitted to journals for

publication and undergo what's called peer review; yes?

A- Yes.

Q- And that's what happened here?

A- Yes.

5 Q- And am I correct that the first journal that it was submitted to was the Canadian Medical Association Journal?

A- Yes.

10 Q- And I suggest to you that it was this very document, RJR-160, dated January, nineteen eighty-six (1986), that was submitted to the Canadian Medical Association Journal?

A- Which one is 160?

15 Q- The one you had in front of you, the one dated January, eighty-six ('86) with your name on it.

A- That's -- I can't be sure it is, because it doesn't have the tables in it and I don't recall exactly what version was sent to the journal. This went through several drafts.

20 Q- Well, the fact is it was rejected by the Canadian Medical Association Journal; wasn't it?

A- Initially it was accepted with revisions, but then the editors changed and the revised version was rejected.

25 Q- Well, wait a minute. What do you mean initially? When was the initial? We have this paper dated January,

nineteen eighty-six (1986). When do you say it was accepted originally?

5 A- I don't recall the date, but we submitted -- as I recall, the paper was submitted. We were sent back referee's comments, we revised the paper, we sent it back and then it was rejected.

Q- Well, I'm going to suggest to you it was never accepted, whatever. It was rejected out of hand by -- with the referee's comments?

10 A- Well, it's not accepted until it's accepted, but the -- I believe there was a round in there where we were asked to resubmit with revisions, which is normally associated with being accepted, but obviously until it's in the journal and printed, it's not in.

15 Q- Well, if there is such a thing, undoubtedly you'll get the opportunity to show it to us, but I'm going to show you a letter from the Canadian Medical Association Journal dated November the fifth (5th), nineteen eighty-six (1986) to Mr. Collishaw. Again, this is a government production. It has government production numbers on it.

20 Me EVRAIRE:

25 Well, again, I'll correct my friend. It was in the government files. It's not something produced by us for the purpose of relevance or anything else.

Q- Yes. Anyway, my question was, is Morgan the same Morgan who you and -- who collaborated with you in one (1) of the publications that we reviewed yesterday?

A- Yes.

5 Q- It's the same Morgan, yes?

A- Yes.

Q- All right, let's just read what Dr. -- is it Dr. Morgan or...

A- Yes.

10 Q- Yes, it is Dr. Morgan -- what Dr. Morgan or Dr. Squires said to you. By the way, Dr. Squires is presently the editor...

A- Yes.

15 Q- ...as I understand it, of the Canadian Medical Association Journal, yes?

A- Yes.

Q- And he's the overall editor of the journal, isn't he?

A- I'm not sure of his exact title.

Q- Well...

20 A- He's certainly the scientific editor.

Q- So he's not just some -- some unqualified person in there, he is the present editor of the journal as I understand it?

A- Yes.

25 Q- The -- what Dr. Morgan and/or Dr. Squires says is this:

"The paper by you, Dr. Tostowaryk and Dr. Wigle, has now been reviewed. We regret the length of time it has taken us to produce this review. It is a situation we run into sometimes with manuscripts that are submitted in the summer. When we reviewed the paper initially, we considered returning it to you as being too specialized for our journal but because of the possibility that this paper would belong with the impressive body of work that you and Dr. Wigle have already published in the C.M.A.J., we decided to have a statistician review it."

I'm just stopping there. I don't read into that that there was ever a submission of this paper between January, nineteen eighty-six (1986) and the summer when apparently the paper -- this paper was submitted, that was accepted. That's not what I would take from what Dr. Morgan says there but maybe there is something we don't have. Does that refresh your memory, Dr. Wigle?

A- Well, I know there was never a version that was accepted. I thought because of the long time interval it had been returned for revision but apparently we didn't get a chance to revise it.

Q- Well, are you withdrawing what you said because I -- I

read from this that it was only submitted once, that their initial reaction was to reject it out of hand as being too specialized but because of their association with you, they decided to review it more carefully.

5 They did, it took a long time, and here's the letter?

A- Yes.

Q- That's more likely what happened, isn't it?

A- Yes.

Q- "In summary ..."

10 -- Dr. Morgan goes on --

"... in summary, the main objections to your presentation are:

1. The application of stratified relative risks derived from old American data to the current Canadian population, that is using the Hammond and/or Godley American data."

15

That's what he means, isn't it?

A- The Godley data.

20 Q- All right.

"2. The inexplicable irregularity of those relative risks.

3. The lack of novelty of the findings.

4. The technical problem of attribution of

25 death to smoking, especially in regard to

5

death from coronary heart disease, in which there are important etiological co-factors and a number of confounding variables that are not accounted for in the paper. In addition, from the editorial point of view, the paper's concern with methods puts it somewhat outside the scope of our readers' interest.

10

We feel that the importance of the topic does not overcome the concerns about the paper's technical problems and lack of appeal to the general reader, we regret that we cannot consider the paper for publication and hope the reviewers remarks will enable you to prepare the paper for a more specialized journal."

15

So it was rejected, yes?

A- It was rejected on the recommendation of one (1) statistician. Normally, the Canadian Medical Association Journal uses at least two (2) reviewers.

20

Q- Is the -- is the answer to my question: yes, it was rejected?

A- The paper was rejected based on the recommendation of one (1) statistician.

25

Q- Well, let's look at the next -- the very next page that's attached to this because it is the report of the

statistician that we referred in the letter, and you'll see at the very top -- it's a little blocked out in my copy but its readable. C.M.A.J. reviewer report, gives a reference number, reviewer number two (2). It appears that whoever this -- and, as you say, they are anonymous. Whoever this reviewer was, he was reviewing -- he was described in this -- in his own document as reviewer number two (2)?

A- That's true, but what happens is that when the journal gets papers, they send them out to our reviewers who they number. It looks like reviewer number one (1) did not reply or did not reply in time because otherwise that reviewer's report would have been included. So they heard from reviewer number two (2).

15 Q- Okay, let's just see what reviewer two (2) said, who was a statistician, right?

A- Yes.

Q- He says:

"The finding ..."

20 -- which he puts in quotation marks --

"... that in 1983 around 34,000 deaths in Canada of persons aged 35 to 84 -- or roughly a quarter of all deaths in this age group -- could be attributed to tobacco use will oppress neither the smoking nor the

25

anti-smoking lobby. It is in no way exciting,
and for obvious reasons it is close to
expectation from U.S. experience. The methods
..."

5 -- also in quotations marks --

"... of obtaining that estimate are not
particularly useful. There must be grave
doubts about confining results from surveys
nearly 20 years apart in 2 different
10 countries."

Now, that means -- that's the combining of the Godley
survey in the sixties (60s) on the one hand and the
population attributable risk figures from the nineteen
eighties (1980s) in Canada. That's what he means, isn't
15 it?

A- Yes, he's referring to the second method.

Q- Yes. And then he deals with the question of
originality. And he says:

"It would seem to be an attempt to gain public
20 mileage out of a Ph.D. ..."

-- and it must be a Ph.D. thesis. Next page:

"Are the conclusions justified? Not in my
view ..."

-- says the statistician. On page three (3) it is
25 stated that -- last paragraph -- that:

"Cancer, coronary heart disease and chronic obstructive lung disease account for only about 70% of the excess deaths among smokers. Then the estimate of 32,200 tobacco-related deaths in 1983 obtained as specified proportions of death from these causes should be multiplied by 100/70. This correction yields an estimate of 46,000, which is far from the figure of 33,603 obtained by the preferred, or method #2. Yet in the first sentence of the discussion, page 8, it is stated that the 2 methods for estimating deaths attributable to tobacco use presented here produced similar results, as they do not, says the reviewer. Which estimate is closer to the truth?

It is possible that the two estimates are compatible, that would be so if their errors were as high as this reviewer believes they may be. However, the problem of errors is not dealt with adequately: see below."

Let's look at the -- at some of the other criticisms.

Under the heading: "Are the Tables and Figures

Helpful and Clear?" And he deals with Table 1 and then he deals with Table 2, and let's see what he says about Table 2, which deals with method two (2), as I understand it.

5 "As columns 1 and 2 are given ..."

-- this is the last paragraph on the page --

"... are given for each of 10 age groups, sex by sex, it is natural to try and identify patterns. In fact the figures vary in quite
10 astonishing fashion without any of the regularity usually found in corresponding new material."

And he says:

"This raises a question related to the paucity
15 of data. Is the lack of pattern real or does it reflect mainly sampling error?"

And then he goes on.

And then let's look at the next page.
"Does the method examine the problem studied?
20 Yes, with important provisos. First, are the relative risks based on 20,000 deaths, 1968 in the U.S., in any way relevant to Canadian experience in the 1980s?

Second, can smoking histories, provided
25 by surviving family members of the deceased be

considered in any way comparable to those
obtained from a sample of adults through
household interviews?"

In other words, the Godley method being the -- derived
from the family members of the deceased and the
population attributable risk by the sample of adults
through household interviews. That's what he's talking
about; isn't it?

A- Yes.

10 Q- Yes.

"Third, do ever smoked and never smoked mean
the same in all situations for which
comparisons are made?

Fourth, is the difference between
mortality of ever smokers and that of never
smokers truly an excess attributable to
smoking? The answer to this last question is
a clear no, unless the characteristics of ever
smokers and never smokers were closely similar
in all respects, in all relevant respects,
within each age group for each sex, e.g. or
that is, same socio economic status, same
environmental exposure, same lifestyles, other
than smoking, same ethnic origins."

25 And on the next page, the reviewer goes on to say:

"This reviewer's opinion is that the provisos
have not been met or at least have not been
shown to have been met."

So based on, in part at least, that review, the Canadian
Medical Association rejected this for publication;
right?

A- Yes.

Q- Now, is that peer review?

A- It's peer review by one statistician.

Q- Yes. Well, it's not peer review by one statistician,
it's peer review by one statistician who gave by -- and
that's all they told you about, but who gave a report
which was then reviewed by the scientific editor of the
Canadian Medical Association Journal, Morgan and
presumably Squires, who is also a scientific editor or
the editor of the Canadian Medical Association Journal.

Is that peer review or not, Doctor?

A- It's peer review, but not the normal peer review that
C.M.A.J. does.

Q- Well, it's peer review that you didn't like very much,
did you?

A- Well, we've had other papers rejected and we've revised
papers. The peer review process is designed not just to
reject papers, but to help the authors improve them and
sometimes publish them in a more appropriate journal.

Q- Yes, but the fact is, Doctor, that notwithstanding that criticism, none of those criticisms were met in the final published paper. If we look at the final published paper in the Canadian Journal of Public Health, no significant change was made in the results that related to any one of those criticisms, was there?

A- The -- okay. The answer is: no. The explanation is as follows.

THE COURT:

Good.

Me EVRAIRE:

Now, we're getting somewhere.

Me BAKER:

See, Mr. Cherniak, if you say it often enough, people start believing it.

A- The -- okay. This referee makes some points. Some of them are more valid than others. For example, are the old U.S. relative risk estimates applicable to Canadian population in the nineteen eighties (1980s)? The answer is yes and no. The -- no, it would be preferable to have more current estimates from Canada. The answer is yes, in that the relative risk estimates from the Godley study were undoubtedly the best available at that time -- at least when broken down by sex and age.

What the referee seems to miss, though, is the

strengths of the first method which is based entirely on Canadian data and which did control for other risk factors. The referee seems to think that all we looked at was smoking. In fact, in the Nutrition Canada Cohort on which the first method is based, we looked at cholesterol, high blood pressure, alcohol, obesity and so -- diabetes and so on. The relative risk estimate that we used from the Nutrition Canada Cohort in method one (1) was adjusted for the only two (2) risk factors that affected the smoking relative risk and that was hypertension and diabetes. We did not find that cholesterol was a confounder.

So, yes, this statistician raised some valid points about method two (2), seemed to ignore the strengths of method one (1).

Me CHERNIAK:

Q- So the fact is that when you resubmitted the article to the Canadian Journal of Public Health, in effect it was the same article without any changes, wasn't it?

A- I think we added the confidence limits in Table 2.

Q- Yes. And of course, ultimately you added in figures for nineteen eighty-five (1985) using the same methods, didn't you?

A- The final version has nineteen eighty-five (1985), yes.

Q- Yes. Now, you next submitted it to the Canadian Journal

of Public Health...

A- Yes.

Q- ... another publication in which you had written from
time to time?

5 A- Yes.

Q- And among the people on the editorial board of that
publication is yourself?

A- Yes.

Q- And you had been for some time?

10 A- Yes.

Q- And it underwent peer review as well, did it not?

A- Yes.

Q- And the peer review that it underwent there was mixed.
One peer reviewer thought that it was wonderful and
should be published immediately and the other one
thought that it should be totally rejected, right?

15

8/0041

A- Yes.

Q- Let's take a look at the breakdown of that. I'm showing
you a letter to Mr. Collishaw dated May thirteenth
(13th), nineteen eighty-seven (1987), from the Canadian
Journal of Public Health.

20

THE CLERK:

RJR-163.

Me CHERNIAK:

25

163.

Q- And just looking at the letterhead, we see your name there. These people on the left-hand column are what, members of the editorial board?

5 A- I didn't know the list was that long, but I assume we're all members of the editorial board.

Q- Yes, and there's you and there's a man named Fernand Turcotte as well.

A- Yes.

Q- And who is he?

10 A- He's...

Q- He's the gentleman who's been sitting in this courtroom for the last while, isn't he?

A- Yes.

Q- Another government witness?

15 A- Yes.

Q- Yes. All right. And this letter dated May thirteenth (13th), nineteen eighty-seven (1987), to Mr. Collishaw and it's "Re: mortality attributable to tobacco use in Canada", and signed by Dr. Last, the scientific editor of that journal. Am I correct?

20 A- Yes.

Q- Who says that he is interested in publishing the article in the journal:

25 "Some revision is necessary before we can proceed. Please consider the comments made by

our reviewers, copies enclosed, and make your revisions as you think best. Once the revised copy is returned to me it will be edited for publication as soon as possible."

5 And in fact, it was ultimately published in that journal?

A- Yes.

Q- And let's look at the two (2) peer reviews that were done here. First of all, is this peer review?

10 A- Yes.

Q- It qualifies under peer review?

A- Yes.

Q- All right. And reviewer one (1), we have a one (1) page report in which he gives the highest rating for -- for
15 everything, and says "Published as highest priority", and says:

"These are extremely important data. Please make available to potential users (activists in the campaign against smoking) by publishing
20 as soon as possible. This paper is well written and, in my opinion, needs no revision. There are a few typos; see abstract."

Would it fair to say that this anonymous reviewer was probably anxious for whatever reason to assist those
25 potential users that he describes as activists in the

campaign against smoking by getting this material out to them as soon as possible? Would that be a fair inference?

Me EVRAIRE:

5 Objection. That's not an answer that this witness can give to this Court.

Me CHERNIAK:

Anybody who reads it can give that answer.

Me EVRAIRE:

10 Well, anyway my friend puts the question and I make an objection to it.

THE COURT:

You're asking him an opinion which is not within his boundaries as expert.

15 Me CHERNIAK:

As long as we get it.

THE COURT:

If anybody can do it, I mean...

Me CHERNIAK:

20 As long as we can have that ruling applied throughout, My Lord, I'm content. I guess, My Lord, some things are too obvious for words.

Q- So that's the one -- that's one of the peer reviews, not very helpful, hardly -- hardly critical, is it? Would
25 that really qualify in your view as critical,

intellectually rigorous peer review?

A- No. This seems to be -- this first reviewer seems to have gone through it quickly and not taken time to raise any critical points whatsoever. This is not uncommon in peer review. It's very common to get back two (2) or three (3) peer review reports, one of which says it's the greatest study ever written and another says it should be shredded and forgotten ...

Q- Yes.

A- ... and then the scientific editor has to judge which referee to believe.

THE COURT:

Q- Obviously he or she was enthusiastic about it.

A- Yes.

Me CHERNIAK:

Q- But then we have another reviewer whose ultimate opinion was: "Reject the manuscript" and who gave it a rating for originality of two (2), importance: the lowest of four (4), clarity: three (3). He said:

"The aims are clearly stated: yes.

Supporting tables are clear and relevant:

yes. Do the results appear valid: no.

Are the conclusions justifiable on the

basis of the facts presented: no."

-- and advised that the manuscript be rejected, and who

said in a typewritten report:

"This is a very interesting paper on an important public health problem. The paper is well written and the data analysis appear to be appropriate. However, the validity of the results are in question for the following reasons.

1) The data sources used for the calculation in columns 1 and 2 in Table 2 are unpublished. The conclusions of importance as that -- as have been derived from this paper should be based on data sources that have been validated.

2) Mortality from smoking depends on the amount smoked, duration of smoking and pattern of smoking in relation, et cetera. It is simplistic to apply a ballpark relative risk. In fact, what is used in the paper appears to be the odds ratio to all the ever smoked category, which presumably includes short-term smokers as well as smokers."

Now, just stopping there. Did you get for us the definition that was used for "ever smokers"?

A- Yes.

Q- And what was it?

A- Ever smokers in Method one (1), which is the -- based on the Nutrition Canada cohort, were people who had smoked for at least -- at least one (1) cigarette per day for at least one (1) year.

5 Q- So -- so you used -- in Table 1, you considered as equal in value, determining who the smokers were, a person who smoked one (1) cigarette a day when -- when he or she was a teenager, for a year and then quit. And as far as your paper is concerned, that's the same as a two (2)
10 pack a day smoker for forty (40) years? They're both ever smokers, right? Yes?

A- The answer is yes, they are both categorized as ever smokers but the -- the effect of this in determining the relative risk for ever smokers is to -- to arrive at a
15 risk estimate that represents the average overall types of ever smokers. Some of whom smoked very little, others of whom smoked a lot, but it's the average risk for that group of people categorized as ever smokers.

Q- But the fact is that in the mid-nineteen eighties
20 (1980s), approximately three and half ($3\frac{1}{2}$) to four (4) million Canadians had quit smoking? In other words, three and half ($3\frac{1}{2}$) million Canadians were former smokers, just based on the rough one (1) to ten (10) ratio that we Canadians seem to like to use when
25 compared to the American statistics, right?

A- I don't know that that's true.

Q- Yes; and we've heard Doctor Doll say that, as I think we talked about yesterday, that the risk goes down or doesn't increase, doesn't go down significantly or, at the very least, doesn't increase when people start -- when people stop smoking?

A- He was referring to lung cancer.

Q- Yes.

A- Not coronary heart disease or emphysema or stroke.

Q- All right, at any rate, as long as we now know who is contained in these ever smokers -- of course, the -- the percentage of ever smokers gets up to, in most of these tables, somewhere between seventy (70) and eighty percent (80%)?

A- Yes.

Q- Yes, and of course, we know that the current smokers are...

A- For men, that's true.

Q- Yes, and -- but in fact, current smokers amount to something under thirty percent (30%) for men, amount to something under thirty percent (30%) of the population, isn't that true?

A- As of nineteen eighty-five (1985), among ever smokers, about forty percent (40%) were current smokers -- this is men, and about thirty-five percent (35%) were

ex-smokers.

Q- And for females, the figures are lower?

A- For females, about twenty-five percent (25%) were
current smokers and about twenty-two percent (22%) were
ex-smokers.

Q- Yes, and those figures have gone down since?

A- Since nineteen eighty-five (1985).

Q- Yes?

A- Yes, undoubtedly, they've gone down a bit.

Q- Yes. Any rate, what the reviewer here was saying, that
he's criticizing the paper because the ever smoked
category presumably includes short-term smokers as well
as ex-smokers and -- but the paper makes no allowance
for either that factor or the amount smoked, duration of
smoking, pattern of smoking, inhalation, et cetera, and
the reviewer is correct in stating that the paper makes
no allowance for any of those things, isn't the
reviewer?

A- No, the reviewer is not correct.

Q- Not...

A- Because the -- the relative risk estimate for ever
smokers that's used in method one (1) is the average
risk for -- for smokers of any type, current or ex --
two (2) pack a day or two (2) cigarettes a day. It's
averaged over the whole group. If you broke that down

into current and ex-smokers, it would be higher for current and lower for ex and higher for heavy smokers than lighter smokers, but the average is valid for the whole group.

5 Q- The -- what's the definition of ever smokers for method two (2)?

A- It would be whatever method -- whatever definition was used in the nineteen sixty-six (1966) or sixty-seven ('67) survey of smoking habits that Godley used.

10 Q- And you don't know that?

A- Well -- no, I don't, but I can say that normally in these surveys the definitions are quite similar. Usually some effort is made to get -- to not include as smokers or ex-smokers people who just barely experimented with smoking. Often the limit used is a hundred (100) cigarettes in a lifetime or the equivalent in other forms of tobacco.

15 Q- So, what you're saying is that although this is your paper, a) you don't know what the definition of ever smoker is in Table 2? Am I correct -- you simply do not know? You -- you cannot tell us what the term ever smoker means in your own paper re Table 2 -- is the answer to that question yes?

20 A- No, the answer is no, I can't tell you for sure.

25 Q- No, you can't tell me.

A- Which -- which the -- the implication, though, is that regardless of what definition they use, the -- let's, for example, in the Godley study, if they used one (1) definition in the survey and another definition in the mortality part, that would be not ideal but it would not change the relative risk estimates very much. It would only be, at most, a small change in the relative risk estimate.

Q- Doctor, I'm trying to determine the intellectual rigour that was applied to the preparation of this paper. Is the answer that you cannot tell us what ever smoker means in the -- in tab -- in the published paper, we have Table 2 and in Table 2 is column one (1), "Relative risk for ever smokers", column two (2), "Proportion of ever smokers in Canada" and I am asking you, Doctor, tell me what the definition is that was used by you and your colleagues for the words "ever smokers" that are contained in your own table, and you're telling me that you can't tell me that?

A- I told you that I could tell you the method for method one (1), that I'm not sure of the method used in method two (2).

Q- Yes, and -- but it may be something like ever smoker may be, as I understood what you said a few minutes ago, it may be something like anybody who has ever smoked a

hundred (100) cigarettes in their lifetime is classified in the ever smoker category?

A- That's a definition that's commonly used.

Q- Commonly used, yes. Okay, at any rate, dealing with criticism two (2) by the reviewer from the Canadian Medical -- from the Canadian Public Health Journal -- Canadian Journal of Public Health, he made a criticism about the mortality estimates and in the -- and you ultimately paid no attention to that criticism, you made no change, did you?

A- You're referring to point number two (2)?

Q- Point number two (2)?

A- So what is the question?

Q- The question is that you paid no attention to that criticism when you resubmitted the paper, didn't have any changes in it that relate to that criticism, right?

A- The -- we did not change our relative risk estimate because the referee's point is not valid.

Q- Well...

A- When we...

Q- Is the answer no? I mean...

THE COURT:

Well, no, your question was two-fold. Did you pay attention? He may have paid attention. Did he make any changes, the answer is no, we didn't make any changes.

Me CHERNIAK:

All right.

THE COURT:

But it was two-fold. He may pay attention to somebody
5 saying something but not agree and therefore not change.

This is what he did, as I understand his testimony.

Me CHERNIAK:

Q- So is the answer that you made no changes?

A- We did not make any changes.

10 Q- Thank you. Let's deal...

THE COURT:

Would that be time for a break?

Me CHERNIAK:

Yes, good time.

15

SHORT RECESS

Me CHERNIAK:

Q- Now, criticism number three (3), the reviewer says:

20 "Excess mortality from smoking is from causes
which have been shown to be associated with
smoking. It is too casual to suggest that
there is an overall increase in mortality from
all causes as the authors have attempted to
25 show. I did a little bit of calculation from

the published vital statistics as follows ..."

And then he goes on and he lists his calculations and he says:

"Based on his summary, he has reason to
question the validity of the results. As a
result, he said, the paper in its present form
is unacceptable for publication."

Now, am I correct that you did not take into account as well, in the published version, the criticism set out in number three (3)?

A- No, we did not address this criticism because, again, this is an invalid criticism. You will note that his estimate is just for the age group thirty-five (35) to thirty-nine (39) and that he uses for that age range an attributable risk of point three (.3) which is far too low because the circulatory disease in particular, the relative risk and the attributable risk is higher among younger age groups. For example, below age fifty-five (55) approximately sixty (60) to seventy percent (70%) of all coronary heart disease is attributable to smoking and the relative risk, attributable risk declines with age.

So it would have been more appropriate for him to multiply by a figure of the order of point six (.6) or even point seven (.7) than point three (.3). At least

for circulatory disease.

Q- So the answer is no?

A- No for that reason.

Q- Yes, okay. So, so far we've got three (3) peer reviews.

5 One of them is not in any detail and says that the paper ought to be available for the anti-smoking activists as soon as possible. Two (2) of them have detailed criticisms and you have made no adjustment in the paper based on any of those criticisms up to this point; am I
10 correct?

A- Not quite. We did include the confidence limits as recommended by the C.M.A.J. referee. We may have made other changes, I don't recall.

Q- Well...

15 A- The policy of the journal is that when you get criticisms from a referee you should either revise or rebut. So that when we return the paper to the journal we either make the changes the referee asks or we explain in a covering letter why we did not make that
20 change. And then it's up to the journal editor to decide if, in fact, we did what was appropriate.

Q- Well, in fact, if we look at the March seventeenth
(17th), nineteen eighty-seven (1987) draft that's attached to the review, in fact the March seventeenth
25 (17th), nineteen eighty-seven (1987) draft isn't very

different from the version that was published in the journal in nineteen eighty-eight (1988), is it?

A- The estimates of deaths attributable would appear to be identical.

5 Q- Yes.

THE COURT:

What is an "E" code?

A- E code is when diseases are being coded by hospitals, either for hospital records or death records, they
10 assign a three (3) or four (4) digit code to identify the cause of death. E refers to external, which in the case of injuries is external cause of an injury. For example, a motor vehicle accident.

Q- By the way, now I'm addressing my question to the
15 attorneys. Will I ever be provided with the Stats Can. printout of causes of deaths for the eighty-three ('83), eighty-five ('85) and further on? Was that the intention of any of the attorneys to file these?

Me CHERNIAK:

20 I must say I have not given any thought to it. I don't know the answer to your question.

THE COURT:

It's because in many of the reports they do refer to the mortality causes as found in Stats Can., even in Mr.
25 Wigle's report. They only have only bits of these

stats., and I was just wondering if I was going to ever get the whole thing. Quite frankly, I would be very interested in getting it.

Me CHERNIAK:

5 I'll certainly take that under consideration from our side, My Lord. I just can't answer your question at the moment.

THE COURT:

Or maybe it's not Mr. Wigle, maybe it's somebody else.
10 But I've seen it referred -- maybe it's Ferrence -- Roberta Ferrence.

Me BAKER:

Just give us a moment, My Lord, she's coming this week, as you know.

15 THE COURT:

Yes, well, tomorrow, I believe? Wednesday. Well, anyways, that's out of order, but I mean...

Me CHERNIAK:

Well, I mean I suppose anybody can put it in. It's --
20 Statistics Canada material would clearly be admissible, so it wouldn't be -- there's no reason why it can't go in.

Q- The -- well, the -- just looking at what this reviewer did in his criticism, he looked at the nineteen
25 eighty-five (1985) Stats. Canada causes of death and he

took the cancer causes and the circulatory causes and he totaled them and he compared it to all causes and he just couldn't get to your figures.

A- No, because he...

5 Q- Or anything like your figures.

A- No, he could not because he used an invalid method.

Q- Yes. All right. And I'd be correct that if we compared the March seventeenth (17th), nineteen eighty-seven (1987) draft with the published version that is now
10 RJR-159, they'd be very similar, wouldn't they?

A- I assume they're very similar. I haven't compared them line by line.

Q- And I take it that you did resubmit the article to the -- to the journal?

15 A- Yes.

Q- And we don't have -- perhaps you do have, but we don't have the covering letter. Do you have the covering letter?

A- It should be in our files in Ottawa.

20 Q- Yes. All right. Now, can you tell me this. Before there was publication in the journal, was there another internal review of the -- of your paper within the Department of Health?

11/0076 A- Yes, Dr. Krewski of the Environmental Health Directorate
25 was asked to review it.

Q- And as a matter of fact, it wasn't just he that prepared the criticism of it. He and others, including yourself and Mr. Collishaw were involved in the -- in the review?

A- Yes, Neil Collishaw and I met with Dr. Krewski because he's a statistician and he didn't really understand the methods we were using. He's not an epidemiologist. So we had to explain to him what we did and why we did it.

Q- And there was a report prepared called "Mortality Attributable to Cigarette Smoking in Canada - An Overview of Current Risk Estimates", was there not, in February of nineteen eighty-eight (1988)?

A- I don't recall a report.

Q- Well, let's see if I can refresh your memory. RJR...

THE CLERK:

164.

Me CHERNIAK:

Q- We have a covering letter -- we have a covering letter dated February sixteenth (16th), nineteen eighty-eight (1988), from Dr. Krewski to the chief of Biostatistics and Computer Applications Division, Environmental Health Directorate, in which he says:

"Please enclosed find a draft of the summary we have been asked to prepare on smoking mortality."

And he asks the chief for his comments to prepare a

5

A-

0-

25

response variables are considered: all causes
of death when exposure is measured as ever
smoker and death due to cancer, cardiovascular
disease and chronic obstructive lung disease
when exposure is measured as current smoker."

And then he -- then the report refers to:

"Collishaw et al, 1987, have estimated the
number of Canadians that died in 1985 due to
smoking."

And that is the very paper that we've been talking about
that was ultimately published in the Canadian Public
Health Journal, isn't it?

A- Yes.

THE COURT:

So that's the AG -- RJR...

Me CHERNIAK:

RJR.

THE COURT:

... 159?

Me CHERNIAK:

159, yes.

THE COURT:

Okay.

Me CHERNIAK:

Well, yes, it's -- I think, My Lord, that the actual

nineteen eighty-seven (1987) paper would be probably the March seventeenth (17th), nineteen eighty-seven (1987) draft that we just looked at and the final published version is RJR-159.

5 THE COURT:

Ah, okay. I see. It's the draft with the...

Me CHERNIAK:

Because at the time of this memo RJR-159 in its published form would not have been in existence.

10 THE COURT:

Okay.

Me CHERNIAK:

Q- And then it refers to another study by a man named Semenciw in also nineteen eighty-seven (1987), who performed an alternate analysis in which the exposure variable is current smoker and the response is death due to cancer, cardiovascular disease and chronic obstructive lung disease. Both the expected and potential number of years of life lost due to smoking are determined. Who is Semenciw?

15

20

A- Robert Semenciw is a statistician who works in our bureau.

Q- Okay. So this was a review then of -- of two (2) internal products, yours and Semenciw's in effect?

25

That's what this is, isn't it?

A- Yes.

Q- And in effect, you and Collishaw are in part the reviewers of your own work?

5 A- Yes, we are, but that's for the reason I explained previously.

Q- Well, whether -- for whatever reason, this internal review was prepared by, among other things, Collishaw -- among other people -- Collishaw and White?

A- Correct, yes.

10 Q- So apparently, you had some input into its final -- into the final product?

A- My input was limited pretty much to explaining terminology and concepts to Dr. Krewski.

15 Q- Now, let's look and see what it says about your work. This is also a kind of peer review, isn't it?

A- It's not the type of peer review that can be held up as a disinterested peer review. I mean, when you have the authors sitting on the review board, it's not exactly impartial or whatever.

20 Q- Well, with those qualifications, it is still a critical review of your work by your colleagues within the department, with input from you?

A- Yes. Yes.

25 Q- So unlike impartial peer review, your colleagues have the opportunity, when they're doing the review, to sit

around the table and ask the people who did the work themselves why they did what they did...

A- Yes.

Q- ... to justify it?

5 A- Yes.

Q- So in some respects, it's better than impartial peer review, in some respects it's worse? Right?

A- It's hard to say.

Q- Yes. All right.

10 A- There's problems with both approaches.

Q- Well, let's look at item three point two (3.2) on the bottom of page four (4).

"The relative risk of death between ever
and never smokers ..."

15 -- and that's really what you and your colleagues were doing; am I not correct?

A- Yes.

Q- "The relative risk may be obtained from a sample of death records and a survey of surviving relatives or other individuals who would be familiar with the deceased's smoking habits. This is a retrospective approach and is limited by the quality of data obtained from a relative recalling the smoking habit of the deceased."

20

25

But that's what Godley did, isn't it?

A- Yes. The main problem of the Godley approach, whereby people who died could not identify their smoking habits, had to be obtained through a relative. The main problem there is misclassification of smoking status.

Q- Yes.

A- Which would tend to reduce the relative risk estimates.

Q- But the problem is that it suffers from the -- from the fact that it's only as good as the honesty and recall of the relatives surveyed, right, because the person's dead, so you're getting the smoking habits given to you in a survey, perhaps a telephone survey by some relative who may or may not tell the interviewer the truth, may or may not know the truth, and so it suffers from that difficulty. That's what's being said here; correct?

A- Yes, but the most likely effect is to underestimate the relative risk and the number of deaths attributable to tobacco...

Q- Well, we don't know that. They may be underestimated, they may be overestimated.

A- But if the relatives randomly say yes when they should say no and say no when they should say yes, the effect would be to under estimate the relative risk. If they tend to say no, this person did not smoke, when in fact the person did, that would also tend to underestimate

the relative risk, because you would have smokers lumped in with so-called non-smokers.

Q- At any rate, the report goes on to say:

"Recall bias may not be substantial for the presence or absence of current smoking of the deceased. However, if the deceased does not currently smoke, but smoked in the past, misclassification of exposure may be greater. This approach was utilized by Collishaw et al ..."

-- in the paper we're talking about --

"... to estimate mortality due to smoking in Canada."

And then it goes on to indicate what you did. So this confirms that you employed the Godley data from nineteen seventy-four (1974) which consisted of a sample of twenty thousand (20,000) death records from the United States where surviving family members were asked by mail questionnaire to provide information on the deceased's smoking habits. And a relative risk for male smokers at various age levels was determined. So that's the Godley approach that you and your colleagues utilized?

A- Yes.

Q- Yes, okay. And then the second approach is the approach that was also used for the second assumption in

your Table 2, was the -- outlined as the interviewing of subjects concerning their smoking habits and following them until death, which is the prospective method?

A- Yes.

5 Q- And that's the method that was used in the Nutrition Canada survey between nineteen seventy (1970) and nineteen seventy-two (1972)? Yes?

A- Yes.

10 Q- And that's what Johansen did to come up with the relative risk for Canadians?

A- Yes.

Q- And there's a criticism there at the top of page six (6):

15 "However, the 862 deaths observed in the 10 year follow-up period were too few to permit separate estimation of relative risk by 5 year age groups. Since these risks vary by age and sex, the use of Nutrition Canada survey is limited. Notwithstanding ..."

20 But that is the relative risk that you used in the first method in your paper; am I correct?

A- Yes, this criticism is hard to interpret because the relative risk estimates from the Nutrition Canada survey were age adjusted. The -- it seems very likely that
25 even if we could have the Nutrition Canada relative risk

broken down by age, that it would make any material difference in the risk estimate, because we've already adjusted for age in calculating the relative risk.

Q- Well, whatever, it's a criticism and in part it's your criticism. You're in part responsible for this report?

A- In part, but...

Q- Yes.

A- ... reports written by committees tend to not be exclusively your own views.

Q- Now, then it goes on to outline the population attributable risk that you and Collishaw used in the -- in the nineteen eighty-seven (1987) article, and it says:

"Combining the relative risk for ever smokers from Godley 1974 and the proportion of Canadians that are ever smokers from the general social survey of 1985 ..."

-- Collishaw and you estimated the age adjusted population attributable risk to -- for males and females as point three four nine (.349) and point two one three (.213) respectively, which in this draft says:

"This suggests that 34.9 of all deaths among males and 24.3 among females are due to smoking."

There must be a misprint there. I think it means

twenty-one point three (21.3), doesn't it?

A- Yes, it should include the age range thirty-five (35) to eighty-four (84).

13/0046 Q- Yes. And those were the figures that -- that were
5 actually used in your paper, a combination of the -- of Godley's relative risk and the -- and the proportion of Canadians that are ever smokers?

A- Yes.

Q- That's how you get to that number?

10 A- Yes.

Q- So that number of thirty-four point nine percent (34.9%) or twenty-one point three percent (21.3%) is only as good as the combination of -- is only as good as Godley's figures on the one hand and it's only as
15 helpful as knowing that -- what the total is of ever smokers. In Canada, taking into account that ever smokers includes everybody who's ever smoked a hundred (100) cigarettes or more, right?

A- Well, in our study, the method one (1) definition would
20 be three hundred and sixty-five (365) cigarettes or more.

Q- All right. Any rate, if Godley's figures are either in error or not applicable to Canadians, then that affects the usefulness of the -- that affects the validity of
25 the thirty-four point nine percent (34.9%)? Yes?

A- Which is the thirty-four point nine percent (34.9%)?

Q- Thirty-four point nine percent (34.9%) is, as I understand it, a combination of using Godley's relative risk and the proportion of Canadians that were ever smokers, for each age group.

A- No, there seems to be an error, because the -- oh, just a minute...

Q- That's what it says: combining the relative risk for smokers from Godley and the proportion of Canadians that are ever smokers equals the age adjusted population attributable risk. That's what you did in your paper, isn't it?

A- It would appear that this section of this report that we're discussing has at least two (2) errors. The authors -- this committee seems to have mixed up the two (2) methods. The point three four nine (.349) should be point three nine four (.394). So those figures, point three nine four (.394) and point two one three (.213) come from method one (1) which is the Nutrition Canada method and then the mistake is replicated in the next sentence. It should be thirty-nine point four percent (39.4%) of all deaths among males. And then there is a new mistake. Twenty-four point three (24.3) should be twenty-one point three percent (21.3%) among females. So this paragraph is quite misleading.

Q- All right, let's move on. Let's go on to page eight (8) where there is a review of the number of deaths due to specific causes for current smokers, and it just deals with Semenciw's estimate of the impact of smoking on Canadians for certain specific diseases: cancer, cardiovascular disease and chronic obstructive lung disease. And those three (3) comprise the largest percentage of what would be total deaths from smoking. Am I not right?

10 A- Yes.

Q- That would be the overwhelming percentage...

A- Yes.

Q- ... if you just take those three (3). The other causes would be... there'd be some but very few.

15 A- Um...

Q- Yes?

A- Well, I don't know the exact figure but I would think that those three (3) causes would account for the large majority of smoking-related deaths.

20 Q- Okay. And it says:

"... but Semenciw, in 1987, estimates that on the average 26,500 Canadian current smokers die per year from one of the 3 causes. Assessment was not determined separately by 5 year age category."

25

Then the review goes on to say why that figure is different than yours. And it says there are three (3) reasons:

"First Collishaw et al consider all causes of death where Semenciw considers only 3 causes. Second, Collishaw et al employ ever smoking as the measure of exposure, with appropriate estimates of relative risk, ever versus never smoker. Semenciw, however, uses current smoker as an estimate of exposure, thus yielding a much smaller estimate.

Third, the estimate of Semenciw was not age adjusted. Since the relative risk due to smoking decreased somewhat with age and death rates increased with age, the unadjusted estimates overestimate the total number of deaths due to smoking."

So what they're saying is Semenciw, for that reason, overestimates the number of deaths because it's not age adjusted.

"If the data from Collishaw are re-analyzed, adjusting for age, and considering only current smokers, then the estimated number of deaths for 1985 is reduced from (35,131) ..."

-- which is the figure in your paper --

"... to 21,303. Thus the estimate of the Semenciw is reduced from 26,000 to 21,303 simply due to the age adjustment.

5 So what they're pointing out is that if you change your category to current smokers from ever smokers, the number goes down by about forty -- about -- it goes down about -- well, from twenty-one thousand (21,000) -- from thirty-five thousand (35,000) to twenty-one thousand (21,000), and about forty percent (40%). That's
10 correct; isn't it?

A- No.

Q- Thirty-five (35) -- if you reduce thirty-five thousand one thirty-one (35,131) to twenty-one thousand three o three (21,303), I suggest to you the reduction is about
15 forty percent (40%). We can figure it out exactly, but forty percent (40%) of thirty-five thousand (35,000) is fourteen thousand four hundred (14,400).

A- It may be true that twenty-one thousand (21,000) is forty percent (40%) lower than thirty-five thousand (35,000), but the statement that this reflects just the
20 difference between current smokers and ever smokers is not true.

Q- Well, I mean that's what it says.

Me BAKER:

25 Let him finish the answer.

A- The estimate of thirty-five thousand (35,000) includes current and ex-smokers. It was age adjusted. The method one (1) and method two (2). Semenciw's estimate of twenty-six thousand (26,000) is based on a totally different method. It's for current smokers only and it's using the U.S. Surgeon General attributable risk figures of thirty percent (30%) of cancer deaths. Thirty percent (30%) of cardiovascular -- that should be coronary heart disease, by the way -- and eight-five percent (85%) of chronic obstructive lung disease, so that we get from thirty-five thousand (35,000) to something like twenty-six thousand (26,000) using a different method for current smokers. To get down to twenty-one thousand (21,000) we go back to Collishaw et al method two (2) and we -- and we restrict it to current smokers.

Q- Yes.

A- But we're mixing apples and oranges there and it's not at all clear that you go from thirty-five thousand (35,000) to twenty-one thousand (21,000) just by doing A and B.

Q- Well...

THE COURT:

Are you saying that the attributable risks found in the U.S. Surgeon General's report of eighty-two ('82) are

incorrect?

A- No, I'm just saying that say you go from thirty-five thousand (35,000) to twenty-one thousand (21,000) by adjusting simply for ...

5 Q- No, but you say you have two (2) methods. He's using the attributable risk of thirty percent (30%) which he found in the Surgeon General's report of eighty-two ('82) and based on his current smokers. Of course, if you take only the current smokers, you'll have a
10 different figure and that's something else than ever smoked and current smokers, we all agree. But he puts up a factor which is the calculation of attributable risk found by the Surgeon General and gets the figure. The rest is mathematics. Are you saying that the
15 figures used in the Surgeon General's report are incorrect?

A- No.

Q- Because that's basically it.

A- No.

20 Q- Your relative risk is different from the Surgeon General's risk, is it not?

A- Our attributable risk is for all causes of death combined. Your Surgeon General's is broken down for the three (3) main diseases.

25 Q- Yes, but your relative risk for all causes has to be a

combination of all causes.

A- Yes.

Q- It's a mean -- it's an average of all causes?

A- Yes. Exactly. But we can't say for sure that our

summary of relative risk describes all diseases. It means that the Canadian data exactly supports the U.S.

Surgeon General's estimates. To get at that we, for example, for cancer you have to go back to Dr. Miller's report where he estimated for nineteen eighty-seven

(1987) smoking attributed or was responsible for twenty-nine percent (29%) of cancer deaths, which is close to the U.S. Surgeon General, and for

cardiovascular disease, we have to go back to the Nutrition Canada cardiovascular disease report, which is

in the annex, and there we estimated that for men aged thirty-five (35) to seventy-nine (79), forty-six (46) or seven percent (47%) of cardiovascular deaths were

attributable to smoking, and for women about ten percent (10%), which would be consistent with an overall risk of

about thirty percent (30%) for men and women.

But the problem I was having with this section of the report is that by excluding ex-smokers, and by using a different methods, Semenciw arrives at the figure of twenty-six thousand (26,000), but the last sentence states that the estimate of Semenciw is reduced to

twenty-one thousand (21,000) simply due to age adjustment. Well, that's simply false.

5 The estimate of Semenciw already -- which is based on the U.S. Surgeon General attributable risk already allows for the fact that if you take all of the deaths, all of the cancer deaths over the age range thirty-five (35) to seventy-nine (79), or whatever Semenciw used, that the average attributable risk for smoking would be about thirty percent (30%).

10 This last statement is referring -- it's reaching -- well, it's just not true. It doesn't make sense.

Me CHERNIAK:

Q- Now, when you talk about the percentage of deaths that are related to cancer, we have to use that in the sense
15 that we talked about yesterday, that the total of all those percentages doesn't necessarily have to equal a hundred percent (100%). It can be more than a hundred percent (100%) as Rothman pointed out yesterday; isn't that so?

20 A- Yes, the total can be more than a hundred percent (100%) if you don't allow for interactions. The -- we have in the report on cardiovascular deaths in the Nutrition Canada Cohort, we address that point, and using the method of Walter, which allows for interactions in
25 calculating attributable risk, we show that the combined

effect of smoking, high cholesterol and high blood pressure is less than the simple added relative risk or attributable risk.

Q- At any rate, looking at this internal review of your paper and Semenciw's paper, it is -- that you participated in -- it says:

"If the data from Collishaw are re-analyzed adjusting for age and considering only current smokers, the estimated number of deaths for nineteen 1985 goes from the figure that's in the report of 35,131 ..."

-- that was also in the published version --

"... to 21,303."

That's what this says, yes? Have I read it right?

A- Yes, you've read it right, yes.

Q- Thank you.

A- Yes.

Q- Now -- and even that twenty-one thousand three o three (21,303) figure would still be -- would still include people who had died up until age eighty-five (85) wouldn't it, because that's what your figures do?

A- Yes.

Q- So to the extent that some fifty percent (50%) of those deaths are from people aged seventy (70) to eighty-five (85), then if we use -- if we try to determine what the

number of current smokers who died from smoking-related deaths are seventy (70) and under using the rationale for doing so in the earlier departmental report that we talked about earlier today, you'd probably have to change that number from twenty-one thousand three o three (21,303) to about eleven thousand (11,000) because about fifty percent (50%) of the deaths would be people over seventy (70), right?

A- It would depend on the distribution by age of current and ex-smokers. If, for example...

Q- But that wasn't done?

A- If you're excluding ex-smokers, then they would tend perhaps to be -- whatever, younger or older.

Q- Yes.

A- It would make your extrapolation a little shaky.

Q- Well, whatever, it wasn't done. There would be some -- there would be a significant reduction whether it's fifty percent (50%), sixty percent (60%) or forty percent (40%), we don't know, it wasn't done but it wouldn't be twenty-one thousand three o three (21,303), it would be a lot less, right?

A- Yes, if you exclude the deaths attributable to people who smoked in the past but who have since quit. It would appear -- you would probably drop the attributable deaths by at least twenty-five percent (25%).

Q- Yes. All right, and then -- then the next heading in this internal review is limitations on the analysis performed.

5 "A major limitation on the estimate of deaths attributable to smoking in Canada is the reliability of the information on whether an individual has ever smoked, as provided by Godley. Although no such bias, what we call bias exists with the data from Nutrition
10 Canada survey, the sample size was such that it did not allow estimation of relative risk by 5 year age categories."

It just repeats the two (2) criticisms that we talked about earlier: the limitation on the reliability of the
15 Godley survey and the small sample size of the Nutrition Canada in the nineteen seventy (1970) survey.

"It is desirable to have data on smoking habits from live subjects and a large enough sample size to determine age, sex, specific
20 relative risks."

In other words, what the reviewers are saying: we're not sure that the Godley's survey is a very good survey and we know that the Nutrition Canada survey wasn't big enough. That's a paraphrase of that paragraph, isn't
25 it?

A- Yes, but again, they seem -- this report written by a committee seems to be not totally accurate in terms of portraying what the strengths and weaknesses of our study were. For example, the implication of -- of the statement about the Nutrition Canada survey that the sample size was not -- did not allow estimates of relative risk by five (5) year age group, implies that that's a major weakness. In fact, the relative risk was adjusted for age. The -- if we had the relative risks available by five (5) year age group, there would very likely have been very little change in the risk estimates.

Q- And then -- of course, this is a review that, as we know, you participated in.

"A further limitation of the analysis is the lack of adjustment for confounding factors. These are factors that are both related to mortality and unevenly distributed among ever and never smokers. These confounders may increase or decrease the relative risk of death due to smoking and thus alter the estimated number of deaths attributable to ever smoking."

Now, confounding, as we've heard from many epidemiologists, is a major limitation -- or the danger

of confounding is a major limitation on epidemiological research, isn't it?

A- The...

Q- Is it or not, that's the question?

5 A- The answer is neither yes or no. The answer can only be yes when it occurs in a substantive way. If the concern about confounding or bias is -- is large among epidemiologists, we're always looking for confounding or bias to explain data, but in fact, this paragraph, this
10 last paragraph is -- is misleading at it stands. It says that:

"A further limitation of the analysis is the lack of adjustment for confounding factors."

Well, that's not true. It only applies to method two
15 (2), which is the Godley method. As I stated earlier, the Nutrition Canada method, or method one (1), the relative risk for smoking was adjusted for the major confounders which were hypertension and diabetes, cholesterol was not a confounder. Furthermore, a great
20 deal of research has been summarized by the U.S. Surgeon General in his nineteen eighty-nine (1989) report indicating that much effort has gone into explaining the tobacco relative risk based on confounders, and when adjustments are done, very little change occurs in the
25 relative risk estimates for smoking-related diseases.

Me CHERNIAK:

Well, My Lord, the only question I asked him was whether confounding is something that is relevant to epidemiological research.

5 THE COURT:

He answered -- in so many words, but he did.

Me CHERNIAK:

Q- So, your colleagues and a committee that you and Collishaw sat on referred to a limitation on in part
10 your work, is the lack of adjustment for confounding factors which may increase or decrease the relative risk and that are related to mortality and unevenly distributed among ever and never smokers. Whether you agree with it or not, that was the criticism of your
15 peers, wasn't it?

A- Well, yes it was, yes.

Q- Yes.

A- In this report.

Q- In this report; and that reference to the lack of
20 adjustment for confounding factors both related to mortality and unevenly distributed among ever and never smokers, that is very much the same criticism that the reviewer for the Canadian Medical Association Journal made, isn't it? He didn't put it in quite that way but
25 that's what he meant?

Q- Right.

Q- It -- but is that the criticism that that peer reviewer, independent peer reviewer made, the same kind of criticism, yes?

10 Q- And is that the same kind of criticism, again expressed
a little differently, that the negative reviewer for the
Canadian Public Health Journal made? He approached it
from a different point of view but he said there's
something wrong with those figures?

Q- Yes.

Q- And would I be correct, sir, that none of these criticisms -- either this internal review that we've just gone over or the two (2) external ones -- caused you or Collishaw to change anything or refer to any of these criticisms in the article that got published that we now have as RJR-159, correct -- yes?

25 A- To answer your question, I have to repeat some of what I
said before.

Q- Why can't you just say yes or no? Did you make any changes between February, nineteen eighty-eight (1988), and the time that the article was published in -- in -- what's the date? I misplaced my 159.

5 THE COURT:

May, June, nineteen eighty-eight (1988).

Me CHERNIAK:

Q- May, June, nineteen eighty-eight (1988), yes, based on any of these criticisms -- or even referred to them?

10 A- The paper that was published included the changes that we did make and the covering letter included the reasons for not making other changes. The -- the major change we did make was to add the confidence intervals. The major change we did not make was to adjust again for
15 confounders that we'd already adjusted for in method one (1) and which could not be adjusted in method two (2) because the information wasn't available.

Q- So -- so much for peer review. It really didn't cause you to change anything from the time that you prepared
20 the article in nineteen eighty-six (1986), which as we know, increased the deaths to thirty-three thousand (33,000) in nineteen eighty-three (1983) to -- from the twenty-six thousand (26,000) or twenty-four thousand (24,000) figure earlier, but really none of the figures
25 changed from the time peer review started in nineteen

5 A- Okay, nothing changed materially, yes -- or no, we did not make major changes. We added the confidence intervals and we did not accept the invalid criticisms about failure to adjust for confounders because we'd already done that in method one (1).

Me EVRAIRE:

15 THE COURT:

LE GREFFIER:

THE COURT:

Me JOYAL:

AUDIOTRANSSCRIPT, Division de Pierre Vigeant & Associés Ltée

Ferrence, en annexe, énumère à la page quarante-neuf (49), je pense que c'est six (6) études de Statistique Canada. Je sais pas si c'est celle-là que vous aviez en tête lorsque vous avez parlé...

5 THE COURT:

Sur les causes de la mort, oui, puis qui me liste seulement que des extraits qui sont tirés de ces...

Me JOYAL:

10 Alors je vais vérifier, parce que dans les annexes aux références, on devrait retrouver ces documents-là, mais je vais m'en assurer.

THE COURT:

Je ne vous oblige pas. Je vous demande...

Me JOYAL:

15 Non non. Non non, Monsieur le Juge.

THE COURT:

... en vous disant que je détesterais pas ça du tout, les avoir. C'est vous qui faites votre preuve.

20 LUNCH ADJOURNMENT

5 Me CHERNIAK:

Me POTTER:

Me EVRAIRE:

In the year of Our Lord nineteen hundred and ninety (1990),
on this thirteenth (13th) day of the month of March,
PERSONALLY CAME AND APPEARED:

5 DONALD T. WIGLE,

WHO, having previously made a solemn declaration, doth depose
and say as follows:

10 CROSS-EXAMINATION BY Me EARL A. CHERNIAK (CONTD),
On behalf of Petitioner, RJR-Macdonald Inc.:

Q- Dr. Wigle, this nineteen eighty-eight (1988) article in
the Canadian Journal of Public Health that was
ultimately published following the peer review process
15 that we discussed this morning was, as I understand it,
the first Canadian study to try to put a number to
mortality attributable to tobacco use in Canada, am I
correct?

A- I think it was the first such effort in a peer review
20 journal, yes.

Q- Yes. Because you do not refer to any other studies on
the same topic in your references in the article?

A- That's correct, yes.

Q- And prior to that time, would I be correct, was that --
25 would I be correct that the rule of thumb that was used

in Canada was since, by some process, in the United States someone had estimated that there were three hundred and fifty thousand (350,000) annual deaths by tobacco use, people had done the extrapolation for Canada by saying: well, we have about ten percent (10%) of the population and therefore the number for Canada must be thirty-five thousand (35,000)? That's what, in fact, had been done up to that time, isn't that so?

5

A- No, not to the best of my knowledge.

17/0111

Q- You've never heard of such a figure being used for Canada, thirty-five thousand (35,000) annual deaths, ten percent (10%) of the United States rate?

10

A- Not by our department.

Q- I didn't suggest it was by your department. I suggested by persons who were trying to put a figure in for Canada, the Non-Smokers Rights Association for one, or groups, activist groups like that that wanted to have a number for Canada. They would simply took -- they simply took ten percent (10%) of the American figure, isn't that so?

15

A- Actually I don't recall that being done, but it might have been.

20

Q- You've never heard the figure thirty-five thousand (35,000) deaths per annum used in Canada by the Canadian Cancer Society, the Non-Smokers Rights Association, any

25

of those groups? Never were aware of that figure being used?

A- Not citing ten percent (10%) of the United States.

Q- Well, whether they cited it or not, had you never heard
5 the thirty-five thousand (35,000) per annum figure before?

A- Before we did our paper?

Q- Yes, before you did your paper.

A- Um -- not to the best of my knowledge.

Q- I see. At any rate, certainly if your paper had used
10 the -- had used the -- used current smokers rather than -- rather than ever smokers, the number wouldn't have been thirty-five thousand (35,000), would it?

A- No, it would have been something less.

Q- Yes; and if your paper would have excluded people over
15 seventy (70), it wouldn't have been thirty-five thousand (35,000), it would have been fifty percent (50%) of that figure, wouldn't it?

A- Approximately, yes.

Q- Yes. And if your paper would have used the original
20 method used by Collishaw and Tostowaryk in the -- for the nineteen eighty-two (1982) estimates, it would have been something less because they only came up with twenty-four thousand (24,000) annual deaths, not
25 thirty-five thousand (35,000), using the Godley method?

Right?

5 A- Well, I'm not aware that that method was applied correctly in that paper. So, if we had done it correctly, we could have come up with a different number.

Q- So, in fact, if you would have applied some of the -- the method -- if you would have taken into account some of the criticisms in the peer reviews of your paper, the number wouldn't have been thirty-five thousand (35,000),
10 it would have been something less, isn't that so?

A- That's not at all clear. The -- we did address the issue of confounding in method one (1). The -- the fact that we used an estimate for a wide age range rather than for five (5) year age groups could have changed the
15 estimate somewhat but probably not in a material way.

Q- And you were aware, of course, as the peer reviewer for the Canadian Public Health Journal who so roundly praised or so fulsomely praised your article, you were aware that this article would, in fact, be used by
20 anti-tobacco activists to widely publicize the number of the Canadian mortality?

A- Yes.

Q- Wouldn't you?

A- Yes.

25 Q- And you did not feel it appropriate to make mention of

the various limitations and criticisms of your article that we've referred to this morning anywhere in your article, did you?

A- We do address some of the limitations of the paper in the discussion.

Q- Well, I guess we can read that for ourselves. All right, those are my questions, thank you.

THE COURT:

Mr. Potter.

Me POTTER:

Thank you, My Lord.

CROSS-EXAMINATION BY Me POTTER,

On behalf of Petitioner, Imperial Tobacco Limited:

Q- Dr. Wigle, I just want to give you a chance to clear up a few things which came up this morning before I move into the questions that I have ready for you. First of all, I understand from what you've said that this article, RJR-159, and going through its various incarnations and through its various peer reviews, you made one (1) substantive change to it and that was to add the confidence levels before it was published, is that correct?

A- That's the main revision that I recall, yes.

Q- And that was the main revision you made after reading

all the comments of the referees and the peer critics?

5 A- Yes, because as I explained previously, the -- when we are faced with referees' comments, we either revise or rebut, and the most substantive criticism was the failure to adjust for confounding which somehow seems to have escaped at least two (2) of the reviewers.

10 Q- Anyway, that was one (1) criticism you decided was correct, of all the ones -- you decided lots of the criticisms were incorrect but the one you decided was correct was the failure to mention confidence levels?

15 A- Well, there's -- we had different reasons for reacting or not reacting to different criticisms. For example, the appropriateness of using "old" U.S. relative risk estimates in a -- in a Canadian population in the nineteen eighties (1980s). We could not fully address that because we did not have a better data set at that time. Now, we would have the American Cancer Society Cancer Prevention Study too, which would be more appropriate.

20 Q- Dr. Wigle, did you decide that the criticism addressed to you on the question of disclosure of confidence limits was well founded or ill-founded?

A- Confidence limits are -- are usually highly desirable in an epidemiology study.

25 Q- So -- so you decided to make that one (1) substantive

change before it went to publication, you put in the confidence limits, is that correct?

A- Yes, we made all the changes that we could.

Q- Yes; and am I correct that between that article and your expert's report, that's the one (1) substantive change between the article and the expert's report, that the confidence limits came out?

A- To the best of my recollection. I haven't sat down and compared the latest draft with what was published.

Q- Yes. Now, in exhibit RJR-164 -- and just so that you know where we are, Dr. Wigle, it's the Krewski memo of February eighty-eight ('88) in which you participated in the way that you described. You gave some corrections to some numbers on page six (6)?

A- Yes.

Q- And I just want to make sure that I understand you correctly. At the bottom of page six (6), you suggested that the number which appears there of thirty-four point nine percent (34.9%) should more correctly read thirty-nine point four percent (39.4%), is that correct?

A- Yes, it's a -- if we look at either that reference, nineteen eighty-seven (1987) Collishaw or the version that was published, which I think is RJR-159, you would see in Table one (1), under "Men," that the population attributable risk is point three nine four (.394), not

point three four nine (.349) and for women it's point two one three (.213), but it's accidentally placed under the total column in the published version.

And then the next sentence repeats the error for men and makes a new error for women.

Q- So, in that one sentence, we have two (2) errors in transcription of percentages?

A- Yes.

Q- Yes. Now, Doctor Wigle, are you saying that you believe that thirty-nine point four percent (39.4%) of all deaths among males are due to smoking?

A- That are due to having ever smoked, either currently or in the past.

Q- Forty percent (40%) of all male deaths are due to having smoked?

A- In the age range thirty-five (35) to seventy-nine (79).

Q- You believe that yourself?

A- Yes.

Q- Forty percent (40%)?

A- Yes.

THE COURT:

Thirty-five (35) to?

A- Seventy-nine (79).

Q- Seventy-nine (79).

Me POTTER:

Q- Now, you've done the calculation for the excess mortality of people who do smoke and of people who have smoked. Haven't you also done some calculations of excess mortality among people who have never smoked at all, but who have simply been exposed to smoke?

A- Yes.

Q- And you've actually calculated, using the statistical methods you've explained, the number of Canadians who die every year from lung cancer, not from smoking, but from having simply been exposed to it?

A- Yes, we published a paper on that topic.

Q- And how many did you calculate died from lung cancer simply from being exposed to tobacco smoke?

A- We prepared two (2) estimates. One was based on epidemiology studies, case control studies of lung cancer, primarily among women who had never smoked but were married to smokers. And using that approach, we estimated that about sixty (60) lung cancer deaths occur annually in Canada among women or men who are exposed to tobacco smoke in the home, but who do not smoke themselves.

THE COURT:

Sixty (60)?

A- About sixty (60). Six zero (60)

Me POTTER:

Q- Sixty (60) deaths. Six o (60) deaths?

A- Yes.

Q- Now, I want to be sure I understand you there, Dr.
5 Wigle. Did you conclude in that work that sixty (60)
deaths occurred in non-smoking spouses.

A- Sixty (60) lung cancer deaths.

Q- I'm sorry. Sixty (60) lung cancer deaths occurred in
non-smoking spouses married to smoking spouses?

10 A- Yes.

Q- Or did you conclude that they actually died from lung
cancer because they happened to be married to a smoking
spouse?

A- The latter, yes.

15 Q- The latter. So you calculated, using your statistical
methods, that there were sixty (60) people in Canada who
died from lung cancer because they were simply exposed
to tobacco smoke?

A- From their spouse, yes.

20 Q- From the spouse. Now, that sounds like a very
manageable number, sixty (60), we're not talking about
thirty-five thousand (35,000) anymore, Dr. Wigle, at
sixty (60) people. It seems to me you should almost be
able to give us names and addresses of these people.

25 Can you identify them at all?

A- We know where to look for them. We can't identify them on an individual basis. We would look among -- primarily among women who have never smoked but who are married or have been married to a smoker. And that's about as far as you could go. Within that group some could have been due to passive smoking and some would be due to other factors, including radon, for example.

Q- Right. Or maybe other factors as well?

A- Yes, there could be other causes that we don't know anything about.

Q- What I'm trying to get at, Dr. Wigle, and you can help me out here by just being direct about it, that number of sixty (60) is the result of a statistical exercise, is it not? You're not talking about actual real people, you're talking about an extrapolation from large numbers down to that small number?

A- Well, to the extent that we were correct in our estimate, they were real people, but we cannot identify which of the never smoking women had their lung cancer caused by their husbands smoking and which had it caused by something else or even an interaction between more than one factor.

Q- And when you say to the extent that we were correct in our estimates, I think I'm correct in saying that this statistical exercise requires the use of certain

assumptions. For example, level of risk, level of exposure. It requires you to assume various things in making your statistical exercise, doesn't it?

A- Yes, there were several key assumptions.

5 Q- And making those key assumptions, you calculated that there were sixty (60) people who died in Canada in one (1) year.

A- Yes.

Q- Because of exposure to someone else's tobacco smoke?

10 A- Yes.

Q- And isn't it -- am I right in saying that when we -- even calculating the thirty-five thousand (35,000), don't you get to the same -- isn't the conclusion the same. It's a stat -- it's a statistical exercise based on the correctness of various assumptions that you make?

15 A- Certainly it is a statistical exercise, but outside of mathematics, virtually everything we know in science is based on statistics. The first and foremost, we have to look at causal relationships and then estimate the impact of a given factor on disease. This inevitably requires a statistical process, but it's not done in isolation from other evidence.

20 Q- That wasn't my question. You've come to the figure of thirty-five thousand (35,000) by a statistical exercise?

25 A- Yes.

Q- And that statistical exercise required you to make several assumptions?

A- Yes. It's the whole basis of science to make assumptions and inferences.

5 Q- There was some mention of water yesterday and of chlorinated water being mutagenic. Do you drink tap water, Dr. Wigle?

A- Yes.

10 Q- Yes. Because you consider it's not that dangerous, when you get down to it?

A- Actually, we recently purchased a water purifier.

THE COURT:

Q- Is that carcinogenic or mutagenic that you said?

Me POTTER:

15 I meant to say mutagenic. If I said...

THE COURT:

Q- Yesterday, did you say mutagenic or carcinogenic?

20 A- It's definitely mutagenic after chlorination and it may be carcinogenic because at least one (1) large case control study of bladder cancer is showing that people who drink chlorinated water supplies for forty (40) or more years have an increased risk of bladder cancer, but it's not known that all the mutagens cause cancer.

Me POTTER:

25 Q- All right. The fact that it is mutagenic does not mean

that it is necessarily carcinogenic?

A- No, it's a warning that there may be a danger.

Q- Okay. Now, besides that, the mutagenicity of tap water which has been chlorinated, there are various other elements in tap water which have been called dangerous by various people, aren't there, Dr. Wigle?

A- Yes, some people still think that fluoride is bad for your health.

Q- Yes, we're not talking about just fluoride. Are you aware that in the tap water of Toronto there is bromodichloromethane?

A- That's a product of chlorination, yes.

Q- And is that a product that you don't want too much of?

A- Certainly.

Q- M'hm. And what about dibromochloromethane?

A- Similarly, it's another product of chlorination.

Q- What about barium?

A- Barium is not very toxic.

Q- No? You can take a lot of that and not worry?

A- I could take some.

Q- Chloroform, is that in Toronto tap water?

A- Yes.

Q- And would you like to take too much of that?

A- We actually have guidelines for the level of chloroform in drinking waters. It wouldn't be wise to take more

than the guideline.

Q- What about chloride?

A- Chloride is quite harmless, except at massive doses.

Q- Nitrate and nitrite?

5 A- Nitrite can react in the body and form nitrosamines and it can be harmful to young babies.

Q- In fact, isn't -- don't many people believe that tobacco does exactly that?

10 A- Well, tobacco smoke does contain nitrosamines, including some of the most powerful cancer-causing agents known and nitrosamine or nicotine, for example, which is present in tobacco smoke, causes cancer in every species that it's been tested in.

15 Q- And nitrite and nitrate are in Toronto tap water, aren't they?

A- Yes, but we're talking about differences in dose and potency.

Q- Well, that's where I'm going to get eventually. There is strontium as well, isn't there, in Toronto tap water?

20 A- Probably. I don't know.

Q- You don't want too much of that, do you?

A- Not a lot, no.

25 Q- No. In fact, there are several things in Toronto tap water which, depending on their -- the level of their presence in the water and the number of times we go to

A- Yes.

THE COURT:

Four thousand...

Me POTTER:

5 ... one forty-eight.

Q- I then looked at the increase in the deaths attributable to tobacco and calculate one thousand five hundred and twenty-eight (1,528). Is that about right?

A- Yes.

10 Q- Well, right away I stop there, Dr. Wigle, because that's thirty-six point eight four percent (36.84%).

THE COURT:

How much percent did you say?

Me POTTER:

15 Thirty-six point eight four percent (36.84%).

THE COURT:

No, where were you? You said there were four thousand (4,000) new deaths.

Me POTTER:

20 Of which the tobacco deaths are one...

THE COURT:

Well, not -- more deaths.

Me POTTER:

25 ... are fifteen twenty-eight (15.28).

Fifteen twenty-eight (15.28), okay.

Right, which is thirty-six point eight four percent (36.84%).

Thirty-six point eight four percent (36.84%).

Q- Now, both in nineteen eighty-three (1983) and in nineteen eighty-five (1985), Dr. Wigle, the deaths attributable to tobacco were about exactly twenty-six percent (26%) of the total. Can you explain why the additional deaths are so much more attributable to tobacco than the normal deaths, the overall deaths? Is there a reason for that?

A- Well, if the number of deaths tabulated in -- under column number four (4), which is actually two (2) columns, nineteen eighty-three (1983) and nineteen eighty-five (1985), if those are tabulated correctly, the numbers in the final two (2) columns simply come from those two (2) columns multiplied by the appropriate attributable risk from the previous two (2) columns.

Q- Well, I understand that, but the -- you've used the same relative risk for both years, haven't you?

A- No.

Q- I beg your pardon?

A- No.

Q- Doesn't column one (1) ...

A- That's the relative -- okay, the same relative risk, but
5 not the same attributable risk.

Q- I understand. But the relative risk helps calculate,
doesn't it?

A- Yes, but it's influenced by the proportion exposed which
changed between eighty-three ('83) and eighty-five
10 ('85).

Q- Are you saying that it's the proportion exposed between
eighty-three ('83) and eighty-five ('85) which results
in your additional deaths being thirty-seven percent
(37%) attributable to tobacco use?

A- The increase in the number of deaths, to go from
15 thirty-three thousand six hundred (33,600) to
thirty-five thousand one hundred (35,100) is -- what,
about fifteen hundred (1,500) deaths, which is...

Q- Fifteen twenty-eight (1,528).

A- ...about four (4) -- it's a four (4) or five percent
20 (5%) increase.

Q- What I'm saying is of the additional...

A- So it's partially due to the increased number of deaths,
the aging, the slight aging of the population plus the
25 different attributable risk estimates based on the

changes and prevalence of smoking.

For example, if you look at men, age group eighty (80) to eighty-four (84), you see that the proportion of ever smokers increased from point six one (.61) to point six eight (.68). And there's a large number of deaths in that age group.

At any rate, the increase in the number of deaths attributable to tobacco went up by four percent (4%). It looks like part of that was due to just more deaths in nineteen eighty-five (1985) and some changes in the attributable risk estimates.

Q- Well, when we see that -- all of the attributable deaths are, in both years, according to you, Dr. Wigle, or to you and your co-author, twenty-six percent (26%) of all deaths, how does that jive with the forty percent (40%) figure we were talking about before?

A- Well, we're still in the range of about twenty-six percent (26%) of all deaths, roughly. Let's see, thirty-five (35) out of one thirty-three (133). There's about a...

Q- No, you said a few -- Dr. Wigle, a few minutes ago you said that you believed that forty percent (40%) of all deaths among males were attributable to tobacco.

A- Among men. Here we're talking both sexes.

Q- Well, let's look at the men. It's seventy-six thousand

(76,000) total deaths in eighty-three ('83) of which twenty-one thousand (21,000) you attribute to tobacco. That's not forty percent (40%).

5 A- Okay. It's -- first of all, it's a wider age range, secondly, it's a different method. The figures that -- for example, men in nineteen eighty-five (1985), there were almost twenty-two thousand (22,000) deaths attributable to tobacco by this method. That's twenty-two (22) out of seventy-eight (78), which is ...

10 Q- Less than thirty percent (30%)?

A- Somewhere between a third and a quarter, yes. So it's a little under thirty percent (30%) and the Nutrition Canada method estimate was thirty-nine percent (39%).

Q- You said you believed it was forty percent (40%)?

15 A- Well, in round numbers. Thirty-nine point four (39.4), whatever it was.

Q- And here we have it...

A- Thirty-nine point four percent (39.4%) was the estimate from method one (1).

20 Q- Right. Well, here's a table in the thing that you published which says thirty percent (30%)?

A- Yes. So the two (2) methods don't agree, exactly.

Q- Now, of those tobacco-related deaths, the one thousand five hundred and twenty-eight (1,528) tobacco-related
25 deaths, I calculated how many of those were seventy (70)

and over. And the answer is one thousand three hundred and fifty-eight (1,358).

So, suddenly, of the additional tobacco-related deaths, going from eighty-three ('83) to eighty-five ('85), one thousand five hundred...

THE COURT:

Maître Potter, you know what you're talking about, I'm taking notes.

Me POTTER:

Thank you, My Lord. That's why I'm trying to rephrase it so we all get it. So that I understand it myself.

Q- But of that additional number of deaths, that is to say the tobacco related deaths went up one thousand five hundred and twenty-eight (1,528).

A- Over age seventy (70).

Q- No, that's all of them. But those ...

A- Okay. Okay.

Q- ...who are aged seventy (70) and over are one thousand three hundred and fifty-eight (1,358).

THE COURT:

Fifty-eight (58).

Me POTTER:

Q- Now, Dr. Wigle, that's eighty-eight point eight seven percent (88.87%) of your additional tobacco-related deaths are age seventy (70) or over. Now, I'm a layman

in this, Dr. Wigle, I don't know about these statistics, but I've got to say that struck me as rather surprising.

How do we go from fifty percent (50%) overall to suddenly eighty percent (80%), suddenly ninety percent (90%) of the additional deaths are age seventy (70) or over? How do you explain that?

A- Well, you're talking about differences which are actually quite small. The -- for example, men aged seventy (70) to seventy-four (74) there was an increase of ninety-nine (99) tobacco attributable deaths and in the next age group, it's about a hundred and eighty (180). When you start dissecting a table this large, it's often possible to find some oddities in the data, but in fact the summary estimates are in line, the -- there's about a four percent (4%) increase in the number of deaths attributable to tobacco, but if you look in any one age group or deaths over age seventy (70) or some subgroups, you can get larger changes just due to chance.

Q- Due to what?

THE COURT:

Chance.

A- Chance, variation.

Me POTTER:

Q- Chance. Now, did you tell us yesterday that the

relative risk of dying from smoking goes down as you get older?

A- Particularly for cardiovascular disease, yes.

Q- And here we have of your additional deaths, ninety
5 percent (90%) of them are aged seventy (70) or over. It just strikes me as odd; and is the answer the same as the one you've just given that some of these things are just...

A- No, the...

10 Q- ...chance relationships?

A- The -- what happens is although the relative risks, particularly for cardiovascular disease, are much higher for younger people, there's many fewer deaths, so that in older age groups, there's very large numbers of
15 deaths and even a lesser but still elevated relative risk can account for more deaths in the older people than in the younger because you're taking a small fraction of a very large number instead of a larger fraction of a much smaller number.

20 Q- And when you talk about those relative risks, when does a relative risk become meaningful? Does it -- does it have to go over two (2) to be a meaningful relative risk or does it have to be over five (5) or what is it in your view?

25 A- It's not that easy to specify a hard and fast rule as to

when it becomes meaningful. There's two (2) aspects to meaningful, one (1) is is it a cause effect relationship and the other is what is the impact on public health. For example, the relative risk of smokers for coronary heart disease is somewhere in the range of one point five (1.5) to two (2) over an age range like thirty-five (35) plus. This does not sound as impressive as the relative risk for lung cancer which is ten (10) to fifteen (15) for current smokers. However, coronary heart disease is so common, it occurs in such large numbers that a fifty (50) or a seventy percent (70%) increased risk has a huge impact on public health. In the order of fourteen (14,000) or fifteen thousand (15,000) coronary heart deaths per year attributable to tobacco. In terms of whether a relative risk is meaningful as indicating causality, certainly relative risks below two (2), the range that we see for passive smoking, we would never accept that as evidence of cause effect relationship based on a single study. We would require multiple studies pointing in the same direction and ruling out confounding and bias.

Q- Right. So on the coronary heart disease, you have relative risk ratios which are towards the low end of the scale but you use them, nevertheless, to calculate deaths which you attribute to smoking?

5

10

A- Yes.

15

A- Yes.

20

25

conditions like emphysema which is overwhelmingly related to tobacco.

Q- Yes.

5 A- Coronary heart disease we have to talk about smoking, elevated blood cholesterol, elevated blood pressure in the main. But what has been shown consistently in the literature on the coronary heart disease is that smoking is an independent risk factor but even when you adjust for the confounders, the effect of smoking persists. In
10 fact, smoking multiplies the risk of having high serum cholesterol so that if you smoke and have high serum cholesterol, you get a much greater risk than either one alone. The...

Q- Yes, we agree with that.

15 A- Yes.

Q- That's not the point but, for example, you took C.O.L.D. or coronary -- no, chronic obstructive lung disease which you say there, you will find a very high relative risk?

20 A- Yes.

Q- Compared, for example, to C.H.D., coronary heart disease. Why, because you see it very often in smokers. I mean, that's why -- that's how you get to a high relative risk. When you have a C.H.D., you see it
25 regularly but in much smaller percentage. That's why

you have a low relative risk, obviously.

A- Yes, the emphysema occurs very rarely in non-smokers and more commonly in smokers that gives a high relative risk. Coronary heart disease occurs quite commonly even in non-smokers but not in young non-smokers. For example, below the age of fifty-five (55), coronary heart disease is very rare in non-smokers and the relative risk for smokers is -- for heavy smokers can go up to ten (10). For example, an American study of nurses who smoked thirty-five (35) or more cigarettes per day showed a relative risk of ten (10) for coronary heart disease, but that's ten (10) times a very small background risk among never smokers. The attributable risk applied to the number of deaths gives you the -- the, in a sense, the bottom line. For example, if it's coronary heart disease, approximately thirty percent (30%) of coronary heart deaths are attributable to smoking independent of other risk factors, and that's thirty percent (30%) of a very large number. It works out in Canada to about fourteen thousand (14,000) deaths per year, which is more than lung cancer attributable. There's only about ten thousand (10,000) lung cancer deaths per year attributable to tobacco. So it's thirty percent (30%) of a large number. Tobacco -- lung cancer, the smoking effect is in the order of eighty

(80) or eighty-five percent (85%) of a smaller number.

Me POTTER:

Q- Dr. Wigle, what gets into the thirty-five thousand
(35,000) figure, is it the fourteen thousand (14,000)
5 coronary heart disease deaths you've just talked about?

A- Well, using the methods in this published paper, we're
working -- we're starting with any death in the age
range specified. The -- if you approach a disease
specific, then the major diseases, the coronary heart
10 disease, cancer and chronic obstructive lung disease.

Q- Well, I'm trying to find out how many of the thirty-five
thousand (35,000), your guess, died of coronary heart
disease?

A- About fourteen thousand (14,000).

15 Q- About fourteen thousand (14,000)?

A- Yes.

Q- And is it your testimony that those fourteen thousand
(14,000) had no other risk factor except smoking?

A- No, it's my testimony that if those people did not
20 smoke, they would not have died in that age group. They
would have died later.

Q- Is it your testimony that they had no other risk factor
except smoking? You've just said a few seconds ago that
fourteen thousand (14,000) have a relative risk quite
25 independent of other risk factors. Are you saying that

you can say positively that they did not show other risk factors?

A- The...

Q- Are there fourteen thousand (14,000) people who die of coronary heart disease, who smoke but who show no obesity, who show no problem with exercise, who show no problem with cholesterol? Is that what you're saying?

A- No. What I'm saying is two (2) things. One, that the fourteen thousand (14,000) figure is based on relative risk estimates from the Nutrition Canada cohort adjusted for high blood pressure and diabetes, not adjusted for cholesterol because it was not a confounder. Certainly among those fourteen thousand (14,000), some would have one (1) or more other risk factors, the important thing being that if, for example, they had high cholesterol, they had multiplied their cholesterol risk by their smoking risk. So that the smoking risk -- if, for example, all Canadians had low cholesterols and normal blood pressure, the smoking risk would not be as high as it is. It does multiply the other risks.

THE COURT:

23/0066 Q- Yes, but you say Nutrition Canada took into account that fact.

A- Yes.

25 Q- The survey. Therefore they eliminated those factors?

A- Yes, the fourteen thousand (14,000) are those deaths that are attributable to tobacco...

Q- Only. Leaving alone cholesterol?

A- Well...

5 Q- That's why they took into account the confounding effect. Otherwise, they wouldn't take it into account.

A- Okay, the fourteen thousand (14,000) figure is our best estimate of the independent effect of smoking.

Q- Right, independent.

10 A- It does not mean that we know every risk factor. For example, maybe some of the smokers had another risk factor, like lack of exercise, which we had not measured in the Nutrition Canada cohort, which accounted for some of the residual risk attributed to tobacco. So we can't
15 say for sure that all fourteen thousand (14,000) were only caused by tobacco.

Me POTTER:

Q- Of those fourteen thousand (14,000), Dr. Wigle, is it a safe guess that seven thousand (7,000) were over seventy
20 (70)?

A- I wouldn't want to guess. It would be a high fraction that would be over seventy (70), but whether it's fifty percent (50%) or forty (40%) or even over fifty (50%), I'm not sure. You'd have to work it out, but it would
25 be a sizeable fraction.

5 Me POTTER:

THE COURT:

Me POTTER:

Me JOYAL:

15 Me POTTER:

A- 3.3?

THE COURT:

Me POTTER:

25 I'm not a doctor, I have no -- but I admit never having

heard that term. What is sudden cardiac death? Is that sudden death of the heart or a sudden death due to a problem with the heart? What's sudden cardiac death?

A- First, excuse me, where are you?

5 Q- First words of the fifth (5th) line of the first paragraph in chapter 3.3.

A- Cigarette smokers have two (2) to four (4) times the risk of sudden cardiac death compared to non-smokers. About half of all deaths from coronary heart disease
10 occur quite suddenly, outside of hospital, and the victims there are usually dead on arrival at the hospital. The vast majority of these occur very rapidly, either -- certainly less than an hour or a lot of them in less than fifteen (15) minutes. Some of the
15 people literally drop dead from myocardial fibrillation. Others may live a few minutes and then die, but they don't get to hospital alive.

Q- So are we talking about coronary heart disease deaths which occur suddenly?

20 A- Very suddenly, yes.

Q- But that's what it is, coronary heart disease death?

A- Yes.

Q- Yes.

A- Well, that's the -- that diagnosis is based on a
25 previous history, the -- any witnesses of the event.

Q- You're not -- does it include ventricular fibrillation?

Q- And does it include both deaths from heart attack and heart disease?

Q- That's what I'm trying to get at, Doctor. There is a lot of unknown reasons there, aren't there, in those deaths?

AUDIOTRANSSCRIPT, Division de Pierre Vilare & Associés Ltée

epidemiological data?

A- Yes. We look for consistency. We also look for explanations for lack of consistency. For example, the Swedish men here, even those who smoke more than fifteen (15) or more cigarettes per day had a relative risk of -- I believe we're talking current cigarette smokers here, had a relative risk of the order of one point five (1.5) or actually one point seven (1.7), and males in the American Cancer Society, which is at the very top, had a relative risk of about three (3).

One would want to look further to see what is the history of smoking in Sweden. Did it begin in a big way in the nineteen twenties (1920s) like it did in the United States, because it seems to take -- well, the effect of smoking and coronary heart disease takes the order of three (3) decades to show up once the person starts to smoke in any -- the major risk is not seen in less than three (3) decades after starting to smoke. So that some of the differences between countries would reflect long-term smoking patterns. For example, cigarette smoking did not become common in Japan until during and after the Second World War.

Q- And if you turn a few pages further on, Dr. Wigle, to figure 2, you have a similar table for stroke. And here we have -- there are in fact eighteen (18) studies

listed here, Dr. Wigle, ten (10) of which, the bottom ten (10), seem to be under one point five (1.5).

Now, in your opinion is that something that you can use in order to draw any conclusions between smoking and stroke?

A- It's -- let's see...

It looks like it's about six (6) studies that are under one point five (1.5). And for several of the studies we're showing males and females separately, so you know the Swedish survey's there on men and women. It's not two (2) studies, it's one (1) study.

Q- Well, we're showing our different bias here, Dr. Wigle, I'm displaying my bias. I have decided that Canadian Health Survey male and female looks to be one point four nine (1.49), under one point five (1.5).

Anyway, whether you agree with me or disagree with me on that, I think you'll agree that it's either nine (9) or ten (10) of these eighteen (18) studies show a relative risk below one point five (1.5).

A- If you count Canada Health survey it's seven (7) studies.

Q- Oh, I'm sorry, because you're combining Canadian -- that's male and female?

A- Yes, it's one (1) study.

Q- Similarly would the U.S. nurses be one (1) study rather

than three (3)?

A- Yes. That's three (3) different levels of cigarette smoking in one (1) study.

Q- And the Manitoba male and female would be one (1) study?

5 A- Yes.

Q- So you would count six (6) showing more than one point five (1.5) and seven (7) showing less than one point five (1.5), is that right?

A- Yes, the other big difference is that the earlier
10 studies on smoking showed less of a risk for stroke than in more recent studies. For example, the more recent American Cancer Society cohort and the U.S. Nurses study and the Nutrition Canada study and the Honolulu heart study and the Canada Health survey show risks roughly
15 one point five (1.5) or greater. The Canadian Veteran's study showed very little, if anything, in the way of a risk.

It's possible that there's more than one
explanation for these changes over time. The diagnosis
20 of stroke is more accurate now with CAT scans and so on than it was previously. Also strokes tend to develop among the very elderly. There's very few stroke deaths before age seventy (70). But it may be a very long-term effect of smoking that didn't show up in the earlier
25 studies.

5

10

15

20

25

AUDIOTRANSSCRIPT, Division de Pierre Vilain & Associés Ltée

Q- Okay. And that's what percentage of all stroke deaths?

A- Of all stroke deaths?

Q- Yes.

A- Let's see -- it's about thirteen (13,000) or fourteen
5 thousand (14,000) stroke deaths. So it'd be about seven
percent (7%).

Q- Seven percent (7%) ...

A- Below age eighty (80).

Q- And above age eighty (80)?

A- Well, the estimate for tobacco for all ages -- well,
10 thirty-five plus (35+) is just over twenty-four hundred
(2,400), which would be twenty percent (20%).

Q- Twenty percent (20%)?

A- About in the order of sixteen (16) or seventeen percent
15 (17%) of all stroke deaths.

Q- Okay. And you have in front of you a table showing
either ten (10) out of eighteen (18) or -- I forget the
number -- seven (7) out of thirteen (13). Anyway, a
majority of studies showing a relative risk factor of
20 less than one point five (1.5) and you nevertheless give
up to seven (7) -- sixteen (16), seventeen percent (17%)
of strokes and put them into your thirty-five thousand
(35,000) figure; does that seem correct to you?

A- The more recent studies tend to show greater risk than
25 the earlier studies. We note that the lower studies are

from Sweden and Japan...

Q- And Canada.

A- And Japan, where the history of smoking is different from Canada. From the Canadian Veterans study which was initiated in the -- around nineteen fifty-six (1956) or eight ('8), somewhere in there.

THE COURT:

Is Sweden different from Canada?

A- The long-term smoking patterns in Canada and Sweden are quite different. If you look at per capita tobacco consumption the -- England and the United States were the first countries to have very high levels of tobacco consumption. Finland was very early.

The countries that have increased -- Canada increased a lot during the nineteen thirties (1930s), Japan increased a lot after World War II, Sweden, to the best of my memory, is -- did not go up as early as Canada. And never has come as high in terms of per capita tobacco consumption. Even today Sweden is lower than Canada, but I think the important thing is that if you look at the more recently conducted studies, that smoking is causally related to the risk of stroke. How it relates to our thirty-five thousand (35,000) deaths, it could be in the order of a thousand (1,000) deaths. But undoubtedly, there's a causal relationship between

smoking and stroke.

Me POTTER:

Q- Well, I'm going to move on from there. Now, all of this
has to do with your calculation, Dr. Wigle, of what I
think people in your trade call excess mortality.

A- Yes.

Q- Isn't that right?

A- Yes.

Q- Now, what appears in that exhibit, RJR-159, is a
calculation of excess mortality by way of number of
deaths.

A- Yes.

Q- Are there other ways to express excess mortality?

A- Yes, one can look at the effect on potential years of
life loss or life expectancy.

Q- M'hm. And have you done calculations like that?

A- For -- related to smoking?

Q- Let's say relating to anything?

A- We've looked at -- well, first of all, in terms of life
expectancy, we've looked at the effect that eliminating
all cancer deaths would have on life expectancy.

Q- That's not what I asked, Dr. Wigle.

A- And we've also done life table projections for how many
people will die in the future under different smoking
scenarios. That's in a master's thesis by one of our

students.

Q- And, Dr. Wigle, that also has to do with numbers of deaths, doesn't it?

A- Yes, but it's a different method.

5 Q- Right.

A- It's projecting into the future.

Q- What I asked you was whether you had done studies of excess mortality from the standpoint of potential years of life lost rather than through ...

10 A- Yes. Yes.

Q- ... numbers of years?

A- Yes.

Q- You have? Have you done so in relation to smoking?

A- Potential years of life lost?

15 Q- Yes.

A- Yes, that's in at least one (1) report, which is the same master's thesis. I think it's also been reported in Chronic Diseases in Canada, but I'm not sure.

20 Q- And have you done any studies of the potential years of life lost due to the consumption of alcohol?

A- Potential years of life lost?

Q- Yes.

25 A- We've looked at deaths before age seventy-five (75). I think there's at least one (1) article done by Dr. Mao in our group looking at potential years of life lost...

A- ...related to alcohol. Actually I'm not sure whether that's published yet or not.

5 Why don't you have a look at Exhibit RJR-161, Dr. Wigle. And that's the November nineteen seventy-seven (1977) article: "Premature Mortality by Ouellet, Roe, Major and Lance." I draw your attention to page twenty-five (25).

Q- Okay. Now, here what we have, and correct me when I go wrong, but this is something from your department; is it not.

15 A- It's a report from nineteen seventy-seven (1977) from
three (3) people in our department, yes.

Q- Right. Three (3) people in your department; isn't that right?

A- Yes.

20 Q- And correct me if I go wrong, but in this table they try to compare excess mortality due to smoking and excess mortality due to hazardous consumption of alcohol, but both of them they try to express in terms of numbers of deaths and in terms of potential years of life lost; don't they?

25 A- Yes.

5

10

15

20

25

lost really means and, but we do use potential years of life lost in some of our reports because it does give more weight to the deaths at an early age. For example, the deaths from injuries related to alcohol.

5 Q- M'hm.

A- Nevertheless, it's more difficult to convey to people what that means.

Q- But why did you, Doctor, in coming out with your expert report and in coming out with your article RJR-159, why
10 did you decide only to talk in terms of numbers of deaths?

A- I guess mainly for reasons of simplicity. We didn't actively consider potential years of life lost and rule it out. In fact, I believe Dr. Mao does have a report
15 looking at smoking and potential years of life lost attributable to tobacco in the works. We just don't do everything at any one point in time, we do -- we make different decisions for different reasons at different points in time.

20 Q- Well, let's look at page five (5) then of this document?

THE COURT:

Of?

Me POTTER:

The same document, My Lord.

25 Q- And in the third paragraph on page five (5), Dr. Wigle,

and it begins:

"Although potential years of life lost is the preferred method of measuring premature mortality for certain causes of death, there are some notable differences in the relative importance of a particular cause, depending on whether we look at deaths or potential years of life lost between ages 1 and 70."

Do you agree with that?

10 A- Yes and no. We use potential years of life lost a lot, because it does give more weight to the younger deaths, so that it's easier, for example, to convey the importance of injuries and suicide by showing that potential years of life lost is -- for each death among -- the young accident victim, is greater than for someone who dies in their sixties (60s), for example.

15 To say that it's the preferred method, I think it's certainly preferred to these authors, but I'm not aware that the public health community at large has agreed on what is the preferred method. It's a widely used index, but I don't think there's any formal consensus that it is the best measure of premature mortality. It is a very good index.

20 Q- What's your view? Which is it better to use?

25 A- I think my view is expressed by our own work, which is

we use it very commonly, and -- but we don't usually attribute potential years of life lost by risk factor. We're starting to do work in that area. For example, there is this master's thesis by Friedenreich, which does look at potential years of life lost attributable to tobacco.

Q- And it can be done, can it not, Dr. Wigle?

A- Yes.

Q- Yes.

A- Yes.

Q- Okay. Now, I'm showing you an article -- could you help me, Dr. Wigle, and pass a copy to Mr. Evraire.

A- Sure.

THE COURT:

Well, gentlemen, you will be happy to know that I've just terminated my second book.

Me POTTER:

Into Volume III, My Lord.

THE COURT:

And now going on tobacco case, Volume III.

Me EVRAIRE:

It's amazing, My Lord, when you compare the new book to the old, how much thicker, with all the knowledge you've acquired, the other one is now. See how much thicker it is. It's amazing how...

Me POTTER:

It's all that ink.

Me EVRAIRE:

...how you can add that right up.

5 THE COURT:

So, I'm going...

Me POTTER:

Okay, now I want...

THE COURT:

10 Just give me a minute to take the time, please, to enjoy
the...

Me POTTER:

Oh, I'm sorry, that's right, you have to date it, yes.

THE COURT:

15 ...first of three hundred (300) pages, make sure that I
have all the details.

Me EVRAIRE:

Est-ce que les procureurs devraient s'identifier pour le
nouveau livre?

20 THE COURT:

No, you don't need to do that.

Me POTTER:

Q- Now, Dr. Wigle, here we have something which appeared in
June, nineteen eighty-six (1986) issue of Chronic
25 Diseases Canada and it's something that you wrote, I

think, on pages five (5) and six (6) entitled "Health Status Indicators". Did you write this?

A- Yes.

Q- And if we go to the very last paragraph, after you've considered various things in a table, your last paragraph you -- I'm asking you if you wrote this?

"I favour potential years of life lost before age 75 as the best -- as the single best index of the impact of a disease. However, use of a range of health indicators is essential to assess chronic conditions such as arthritis. It is interesting to note that cancer ranks very high as a cause of premature death and hospital days but low on most other indices considered here?"

Did you write that?

A- Yes.

Q- And is it true that you favour potential years of life lost before age seventy-five (75) as the single best index of the impact of a disease?

A- Yes, and in brackets it states there that age seventy-five (75) is the current average life expectancy for Canadians.

Q- Yes, but what you said in that sentence is true, is it?

A- Yes, that's my personal feeling.

Q- And if we look at potential years of life lost due to tobacco use or potential years of life lost due to the hazardous drinking, do you have any view as to which ranks highest?

5 A- We know that very roughly there are about eight thousand (8,000) deaths annually attributable to tobacco -- or alcohol in Canada before the age of seventy-five (75). This is from a paper that we have that's been submitted for publication. These deaths occur on average at an
10 earlier age than smoking-related deaths. If we converted the alcohol attributable deaths to potential years of life lost and did the same for tobacco, my best guess is that tobacco would still come out ahead because there is over four (4) times as many deaths so that even
15 though they do occur in -- at an average older age, tobacco probably would still come out ahead.

Q- And am I right, Dr. Wigle, that that is so if you include the people who have already given up smoking?

A- The thirty-five thousand (35,000), yes.

20 Q- Yes.

A- Yes.

Q- And if you look at current smoking compared to current drinking, which comes out ahead?

A- Well, in terms of death, you're talking in the order
25 of...

A- I think the best way to -- to answer your question would be to do the calculation rather than speculate.

A- But that's using...

A- It's using very old data and it's done using completely different methods.

What page, I'm sorry?

Page twenty-five (25), the table we saw.

A- Yes, the main problem with this report, in fact, just on a quick scan is that the source of the relative risk estimates is old studies. For example, it's the old Hammond study which has -- it was fairly reliable for the estimate for men but it's a gross underestimate of the current risk for women.

25 A- Wynder was for cancer of the mouth, I believe, only, and

again an older study.

Q- So what you're saying is you'd like to use relative risks ratios which aren't too old?

A- Actually, the best available right now would be the American Cancer Society Cancer Prevention Survey II, which only became available in the last year.

Q- So, what I get from you, Dr. Wigle, is that you have a guess but you haven't done the work and you don't know whether current smoking or current drinking results in the greatest number of potential years of life lost?

A- I don't know for sure but certainly they're both -- they're each major problems.

Q- Major problems.

THE COURT:

Is it worthwhile taking a break?

Me POTTER:

Perhaps, My Lord, I'm in your hands. I'll be fifteen (15) more minutes.

THE COURT:

Avez-vous un réinterrogatoire?

Me EVRAIRE:

Oui, environ vingt (20) minutes.

SHORT RECESS

Me POTTER:

My Lord, before moving on, could I produce this as an exhibit, the article...

THE COURT:

5 Oh yes.

Me POTTER:

... of June nineteen eighty-six (1986)? It will be Exhibit ITL-35.

THE COURT:

10 You've been modest.

Me POTTER:

Next to Mr. Earl Cherniak, it is with reason.

Q- I don't know if you know this, Dr. Wigle, but this is a case about advertising and I'd like to talk to you a bit about advertising.

15

In Exhibit RJR-158, which is your nineteen eighty-six (1986) article, "Socioeconomic disparities in risk factors" -- I'm looking at page one thirty-one (131), Doctor, and I'll be talking to you about the right-hand column of that page, the second paragraph which begins "The decline". And what you say here, after a discussion of the socioeconomic disparities in risk factors for cardiovascular disease and after recognizing that there has been a decline in smoking prevalence, you point out that the decline has also been

20

25

inconsistent among socioeconomic groups, that is to say some socioeconomic groups have had incidence declines which are greater than other socioeconomic groups.

Isn't that correct?

27/0092 5

A- Yes.

Q- Yes. And in your job, Dr. Wigle, do you follow statistics about the incidence of smoking?

A- Yes.

10

Q- Yes. And as a general proposition, can we say that the incidence of smoking in Canada has been coming down for a long time?

15

A- Well, the per capita tobacco consumption has been declining since about nineteen eighty-three (1983). The prevalence or the percent of men and women who smoke -- first of all, the percent of men who smoke peaked around the mid-sixties, nineteen sixty-six (1966), it's declined since then; for women, it's -- the trend was somewhat flatter and the sex difference is in the education effect as well.

20

Q- Anyway, the decline among the men, which used to be the big smokers, that started twenty-four (24) years ago, did it?

A- Approximately, yes.

25

Q- Yes. And what you're saying in this paragraph, in this article, is that the rate of decline is different

depending on the socioeconomic group that we look at?

A- Yes.

Q- Isn't that correct?

A- Yes.

5 Q- And you say in that first sentence, or you suggest, you wonder, you say:

"The decline in smoking prevalence by
education level between '75 and '83 suggests
that socioeconomic groups in Canada may vary
10 in their responsiveness to information about
lifestyle-related health risks."

Now, Dr. Wigle, are you saying there that it might be possible that different people in different socioeconomic groups react differently to the health
15 message that the government has been trying to get out about tobacco?

A- That would be at least part of the explanation as to why it seems to be the better educated people who are quitting smoking.

20 Q- Okay, now before we go any further, Doctor, I want to make sure on what basis you're here. I think I'm right in saying you don't have any particular expertise in advertising?

A- None.

25 Q- None. And you don't have any expertise in knowing

either how effective an anti-tobacco ad is or why it --
why it is effective or not effective, do you?

A- No, I can only assess what I read in the literature. I
haven't done any research in that area.

5 Q- And in fact, you have no expertise in that area, do you?

A- No, I haven't done research in that area.

Q- No. So what you say here, in this first paragraph, am I
right in saying it's a supposition, Dr. Wigle, that
you're supposing that it is possible that a different
10 socioeconomic group may react differently to the health
message? You're not saying that that is your opinion,
are you?

A- The -- actually what is stated in that paragraph is --
it's speculation about one thing, one difference that
15 might exist between socioeconomic groups...

Q- Right.

A- ... which is responsiveness to information.

Q- Yes.

A- There are other differences which could account for the
20 observed smoking patterns.

Q- Okay. So it's speculation. And what I'm trying to get
at, Doctor, is that you don't have any particular
expertise to say whether that speculation is correct or
not, do you?

25 A- No, except it does seem to be part of a general pattern

that when health-promoting programs are conducted, for example the introduction of the pap smear to detect cervical cancer at an early stage, these types of preventive behaviours or health-promoting behaviours tend to get picked up first by the better educated and higher income segment of the population.

5

Q- Yes, you can see the pattern, but what I'm putting to you, Doctor, is that you don't have the expertise, and you don't hold yourself out as having it, to tell us what the cause is?

10

A- No.

Q- No. So you can see the pattern and you suspect that this may be an explanation, but you don't know, do you?

A- I think it's quite likely, but I wouldn't -- I wouldn't...

15

Q- Okay.

A- ... go beyond speculation.

Q- Well, the anti-cigarette advertising, do you have any expertise on which to say that that anti-cigarette advertising has more of an effect or less of an effect on people in lower socioeconomic groups? Do you have an expertise on which to say that?

20

A- Just the knowledge I have from reviewing the scientific literature, including articles by people who have done research in that area...

25

Q- M'hm.

A- ... and it would appear that in general, if a new idea, whether it's a health idea or other ideas introduced, it's the more affluent, better educated segment that reacts earlier and the other people tend to react later, in general.

Q- In general. So let's come back to my question. Do you have expertise on which to say that the anti-cigarette message of the government is more or less effective on members of low socioeconomic groups? Do you know whether that advertising affects them more or less than other people?

A- I don't know for sure, but I would suspect that any education done on tobacco would -- up-to-date at least -- would be more likely to reach the higher income, better educated segment and be effective.

Q- M'hm. And you don't have any particular expertise on which to say that advertising is -- that people in -- that poor people are more prone to manipulation by advertising than rich people?

A- No, I don't have any expertise in that area.

Q- No, and you've spoken about the different rates of decline between men and women in prevalence. You don't have any expertise on which to say that women are more prone to manipulation than men, do you?

A- By advertising?

Q- Yes?

A- No, no.

Q- No; and when we were speaking about alcohol before and
5 the serious problem that you called it, you don't have
any expertise on which to say that those people are
drinking to excess because of advertising, do you?

A- Well, people may drink to excess...

Q- I'm asking you if you have expertise, Dr. Wigle, on
10 which to say something like that?

A- No.

Q- No.

A- But I mean there's many reasons other than advertising
for drinking to excess.

Q- Yes. So if we go to Exhibit RJR-150, which is your
15 article "The Tobacco Industry is Still Resourceful" --
and I'm on page fifteen thirty-eight (1538). The
right-hand column, the paragraph -- the second paragraph
beginning "Apologists". You make statements in there
20 about arguments relating to the effectiveness of
advertising. Dr. Wigle, I put it to you that you have
no expertise at all on which to say anything about the
effect of advertising, whether it has an effect on
overall consumption or on market share, do you?

A- The...

thirty-nine (39).

A- Yes.

Q- Yes -- you make statements there about what we might expect to get out of Bill C-51.

5 A- Yes.

Q- And helping us by advertise -- by doing something to advertising which might do something to demand. I put it to you, Dr. Wigle, and I want an answer to my precise question, you don't have any expertise and you are not offered as someone having expertise on the question of the effect of commercial advertising, do you?

10

A- No.

Q- No, thank you.

A- I thought you were going to address this paragraph.

15 Q- Well, I guess I just want to find out from -- from what point of view it's coming but it's not coming from your expertise?

A- No.

Q- No.

20 A- It's more of a personal opinion ...

Q- Right.

A- ...than an expert opinion.

Q- Thank you. Now, let's go back then to Exhibit RJR-150, the article you were looking at before, and do you remember the discussion yesterday about obscenity?

25

A- Yes.

Q- And you -- you stated your view that it was hypocritical and therefore obscene, I think I'm not misstating you, to associate tobacco products with athletic events?

5 A- Yes.

Q- Do you consider it obscene to associate tobacco products with musical events or theatrical events?

A- I consider it, perhaps, slightly less hypocritical than with a -- what's clearly a health-promoting activity, which is exercises.

10

Q- Well, let's deal with the music or the theatre. Do you consider it at all hypocritical to associate tobacco with cultural events, musical events, musical festivals, is it hypocritical, Dr. Wigle?

15 A- I think any activity that's designed to promote tobacco is hypocritical.

Q- Any activity designed to promote the legal product tobacco is hypocritical, is that correct?

A- Hypocritical of society, perhaps not hypocritical of the industry.

20

Q- So anything done in order to sell that legal product is hypocritical, is that correct?

A- On behalf of society, yes.

Q- It's hypocritical on behalf of society?

25 A- To allow the promotion of a product that in the view of

many experts is addictive and which undoubtedly is the major preventable cause of early death in Canada.

Q- Is it therefore hypocritical, Dr. Wigle, to allow the sale of that product?

5 A- Possibly, but there's the political reality that there's still six (6) million smokers in Canada.

Q- That's right, who like it; and now on that same article, Dr. Wigle, you quote at the bottom of that same paragraph, underneath the obscenity business, you quote
10 excerpts from what you call, in that article, tobacco industry reports?

A- Yes.

Q- And from your footnote, I see that you're looking at a staff report on the cigarette advertising investigation?

15 A- Yes.

Q- And, My Lord, you've already seen this. This was Exhibit AG-119. You've also seen, My Lord, Exhibit AG-119-A which were confidential extracts from that staff report. Now you, Dr. Wigle, did you see
20 confidential extracts of that report or did you just see the report itself?

A- I saw extracts. I didn't see an entire report.

Q- You didn't see an entire report?

A- No.

25 Q- No. And when you published this, did you then know that

10

Q- Based on affirmations like yours that if tobacco industry reports showed that. Did you know that there were libel proceedings in the United States based on that affirmation?

Q- When I say libel proceedings, are you at a loss? Is it a complete blank or do you know what I'm talking about?

15

A- Which is Myers et al, staff report on cigarette advertising.

20

A- No.

Q- And were you ever aware of that?

A- No.

5 Q- Even as I ask you the question, you've never heard of that before?

A- Correct.

Q- And when you -- was this your writing or was it Peter Morgan's writing?

A- Well, the except is here, the quotation...

10 Q- The reason I asked the question, Dr. Wigle, is that other questions on this article have elicited a response from you that the writing was not really yours but Dr. Morgan's. Did you participate in putting that in there or was it he?

15 A- Well, we share responsibility for the whole article. In terms of the definition of obscenity, journal editors like to have definitions. But we share responsibility for the whole article.

20 Q- Now, where do you sit in the Department of Health and Welfare? If we look at the family tree inside there, are you in the same branch as Neil Collishaw?

A- The same branch, yes.

Q- And is he above you or below you?

A- Sort of obliquely sideways.

25 Q- Obliquely sideways.

A- Yes.

Q- So do you both answer to the same superior?

A- I report to Dr. Losos who reports to Dr. Liston. Neil reports to Dee Morrison who reports to Claire Franklyn, I believe, who reports to -- or Peter Toft who reports to Peter -- to Roy Hickman who reports to Liston.

Q- Okay.

A- So he's a cousin, second removed.

Q- He's a cousin, second removed, but you both have the same grandfather: Dr. Liston?

A- I guess.

Q- Right; and...

A- Godfather.

Q- So you both report ultimately to him who reports up the line?

A- Yes.

Q- Is that right?

A- Yes.

Q- And when Bill C-51 came out and was attacked in these proceedings, do you know if you received the same instructions as Neil Collishaw as to what to do about Bill C-51? Was your department instructed that it should do what was necessary to protect Bill C-51?

A- No, I was approached directly by Neil to consider providing evidence. The -- I then wrote a memo to my

director and director general requesting permission to provide evidence and that was -- the director general, who is Dr. Losos, discussed it with Dr. Liston and I was given such approval. In fact, I was encouraged to go on and do it.

5

Q- You were encouraged to give that evidence.

A- Yes.

Q- By your department. By your employer?

A- Yes.

10 Q- Is that right?

A- Yes.

Q- Okay. Now, Dr. Wigle, do you remember the discussion of your resignation in November of nineteen eighty-seven (1987) from the Non-Smokers Rights Association?

15 A- Yes.

Q- And RJR-151, which I'm showing you, there is the cover note which went from Dr. Losos to Janice Hopkins. Is that the same Dr. Losos you've just mentioned?

A- Yes, he's our director general.

20 Q- Right. And that's the same Dr. Losos that you mentioned yesterday, the person to whom you had spoken about -- I forget. Did you speak to him about intemperate remarks or about belonging to the N.S.R.A.?

A- The headline in the Canadian Press article.

25 Q- M'hm. And it was -- you sent a copy of your letter of

resignation from the N.S.R.A. to Dr. Losos?

A- Yes. Yes.

Q- Why did you bother sending him a copy of your letter of resignation?

5 A- Well, the earlier discussion I had with Dr. Losos
concerned the article and the appearances that it gave
of intemperate or whatever type of remark, the -- I was
not asked to resign from the Non-Smokers Rights
Association, but I knew that it would probably be well
0.0 received if I did.

Q- He didn't ask you to resign from the N.S.R.A.?

A- No.

Q- But you realized that you were being queried on an appearance of over-activism?

15 A- Yes.

Q- Is that correct?

A- Yes.

Q- And that because of that, you thought you could appear better to Dr. Losos by resigning?

20 A- Well, appear better as a member of the department to the public.

Q- Thank you, Dr. Wigle.

RE-EXAMINATION BY Me PAUL EVRAIRE,

On behalf of Respondent:

Q- Dr. Wigle, let's look at RJR-150 for a moment and let's
refer to the paragraph at page one five three eight
(1538) that my friend -- have you got that before you?

THE COURT:

RJ-150?

Me EVRAIRE:

Q- Let's look at the paragraph that...

THE COURT:

RJ-150?

A- Yes.

Me EVRAIRE:

150, yes, that my friend has put before you. The
paragraph commencing with "Apologists for the tobacco
industry". It starts off:

"Apologists for the tobacco industry ..."

-- the second full paragraph on the right-hand side of
that page --

"... argue that advertising and promotion
introduce new brands and influence brand
selection but do not recruit new smokers."

Q- Sir, is that supposed to be your opinion?

A- This is the rationale that...

Q- Is this supposed to be your opinion? We will go faster

if you just answer the questions, as my friends have encouraged you to do.

30/0040

A- That's my opinion as to the rationale offered by the industry, yes.

5

Q- Okay, but is it an opinion that you hold about why the tobacco industry introduces new brands?

A- No, I do not agree...

Me POTTER:

10

Objection, My Lord. This man has no expertise, no background, no basis, no intelligence, no training, no nothing on which to offer...

THE COURT:

He's intelligent, no doubt.

Me POTTER:

15

He's very intelligent, but none on which to offer an expert opinion on the reason for which the tobacco industry does anything at all.

THE COURT:

20

Be that as it may, I read as well as he can do and when he says after that:

"To believe this, one has to accept that ..."

-- tatati, tatata.

25

So obviously his opinion is that he doesn't believe that. It's in the paper and I can read as well as Mr. Evraire and anybody else.

Me EVRAIRE:

All right. Okay. Thank you, my point is made. Thank you.

Q- Doctor, if we look at your paper on socioeconomic
5 disparities in risk factor for cardiovascular disease, I
won't take you to the conclusions but ask you what is,
from a public health point of view, the purpose of
writing such a paper?

A- The purpose is to identify subgroups of the population
10 where there is still a large problem. Primarily, in
this paper, the risk factors for cardiovascular disease,
if we have succeeded in reducing smoking levels and
cholesterol levels and high blood pressure levels in
some groups, there are other groups in which we have not
15 succeeded, so that the main point is to target such
groups for more effective intervention studies or
programs.

Q- Thank you.

Me EVRAIRE:

20 My Lord, you asked if we would maybe file -- and I think
it might be an appropriate time to file -- the nineteen
eighty-six (1986) excerpt from the "Causes of Death"...

THE COURT:

No, I don't want the excerpts, I want the whole thing.

25

Me EVRAIRE:

Okay. Well, we have ordered that. It will take till Monday. We will make it available.

THE COURT:

5 Okay, there's no rush.

Me EVRAIRE:

Okay.

THE COURT:

I was just wondering.

10 Me EVRAIRE:

No, I wanted to make sure that you knew it was coming. Now...

THE COURT:

I'm not asking, I'm just suggesting.

15 Me EVRAIRE:

No, I understand you're not asking and the record will show that we are offering it of our own volition.

THE COURT:

Okay.

20 Me EVRAIRE:

Q- Doctor, I'm putting before you -- My Lord, I'm looking at Volume XXVII of the transcript, this is Dr. Doll's testimony -- and Dr. Wigle, have you turned to page four two five five (4255)? Just by way of introduction, my
25 friend, Mr. Cherniak, put to you certain statements that

had been made by Dr. Doll and asked you if you agreed with them. Let me put the actual transcript before you and ask if you agree with the statements in that. And I'm reading from line ten (10) of page four two five five (4255) of Volume XXVII. My Lord, if I may follow with my extract with the witness, I'll have this one available if Your Lordship wishes to follow.

THE COURT:

Do you have one?

Me EVRAIRE:

Yes, I'll give you that one.

THE COURT:

All right.

Me EVRAIRE:

Q- Can you follow with me here? So I'll leave it there so I can read it too. At line ten (10), the question by Mr. Cherniak was as follows:

"Yes, well as you've indicated, the question of diet is the greatest single factor for cardiovascular disease?

A: I don't question that.

Q: You don't question that and am I correct that...

A: That wouldn't be true, of course, under the age of forty-five (45), as you appreciate that

we were talking about all ages. Yes.

Q: I will come to that. The fact is that cardiovascular disease is usually the combination of a number of factors.

5 A: Yes."

Do you agree with that statement, Dr. Wigle?

A- Yes.

Q- Right.

"Q: Diet is one of them?

10 A: Blood pressure is another, smoking is another."

Do you agree with that answer by Dr. Doll?

A- Yes.

Q- All right.

15 "Q: I'm sorry?

A: Blood pressure.

Q: Yes.

A: Smoking are the ones.

Q: Yes, obesity, overweight is another.

20 A: I'm not an expert on this. I'm not sure that once you've taken account of hypertension and blood cholesterol, I don't know that obesity then has an effect. There's been a difference of opinion about that."

25 Q: Yes, well, certainly many competent

doctors think that obesity is a contributing factor to cardiovascular disease, coronary heart disease?

A: Not independent of hypertension and blood cholesterol level to my knowledge, but I may be wrong on this."

Do you agree with his answer there, that it is not independent of hypertension and blood cholesterol -- or do you know?

10 A- I agree partially. I agree that it's not independent. That the effect of obesity is not independent of hypertension...

Me CHERNIAK:

My Lord...

15 Me EVRAIRE:

Finish your answer.

A-but instead of saying hypertension and blood cholesterol, I'd say hypertension and diabetes.

Me CHERNIAK:

20 My cross-examination with respect to Dr. Doll's evidence related to what Dr. Doll said about the relationship between cardiovascular disease and diet. And on page forty-two fifty-four (4254) and forty-two fifty-five (4255), Dr. Doll referred to diet as being the greatest
25 single factor with respect to cardiovascular disease,

and has read the witness what Dr. Doll actually said from forty-two fifty-five (4255). Dr. Doll said the same thing on page forty-two fifty-four (4254) at -- between lines twelve (12) and twenty (20).

5 And my friend is now going on to read what Dr. Doll said on other points that I did not put to the witness. I didn't put to the witness what Dr. Doll said about obesity or about cholesterol or things of that nature. And my submission is that I didn't cross-examine the
10 witness on what Dr. Doll said about those points. It's not proper to re-examine him on them.

Me EVRAIRE:

Well, it's my submission in response to that: the purpose of re-examination is to bring out things that
15 ought to have been brought out more fully by my friend. I do note that yesterday, even though I invited him to do so, my friend didn't put the transcript to the witness in this area and, in fact, what, it's my submission, this is doing, is showing that there was
20 more than just diet that Dr. Doll was concerned about. That there were other factors. A point not brought out by my friend.

In any event, we've crossed the bridge that I wanted to cross with this and I've put the questions
25 that I wanted him to agree with.

THE COURT:

I figured you were finished. So under reserve, now that he's answered the question.

Me CHERNIAK:

5 At least I got him to stop reading, My Lord.

Me EVRAIRE:

A bit late.

Q- All right. Perhaps the last area I'd like to refer to is RJR-159, the published article. You have that before you, Dr. Wigle.

10

A- Yes.

Q- And let me ask you right up front, we have marked for identification as RJR-C and D, papers by Messrs. Collishaw and Tostowaryk which my friend has suggested were drafts of the paper as eventually published. Let me ask you point blank, Doctor, did you, in your work, in preparing for RJR-159, use these as drafts, sir?

15

A- The main contribution I made to this paper was method one (1), which I developed independently. Before this paper was written in its final form, I know I saw a draft paper by Collishaw and Tostowaryk, but I'm not sure that it's one of those two (2).

20

Q- All right. Thank you.

THE COURT:

25 Could it be either one or none?

A- I know I saw a draft report, but I'm not sure that it's either one of those.

Me EVRAIRE:

Q- It could have been yet another?

5 A- I don't know how many there were in that series. There could have been several.

Q- You can't assist the Court with an understanding of what you might have looked at, is that what your evidence is?

A- Presumably it was something closer in time to the later
10 report, because they had advanced their work before I got involved.

Q- All right. And my friend also took you through some exhibits this morning -- and let me find the right one here. RJR-163. I put that before you as a letter from
15 Dr. Last, identified as scientific editor of the Canadian Journal of Public Health to Neil Collishaw. You had seen that before today, obviously?

And what my friend didn't put before you, and I would ask if you have a recollection of this, is whether
20 Mr. Collishaw or yourself responded to this letter with a subsequent letter to Dr. Last?

A- I'm sure he did, because if he revised a paper for resubmission, you have to explain why you did it -- did not do all the revisions that the referees request.

25 Q- All right. I'll show you now a letter of July sixth

(6th), nineteen eighty-seven (1987) with attachment and ask if you can identify that?

Don't go through it, but first of all, satisfy yourself that that is the response to Dr. Last.

5 A- This -- I'm sure I saw this, but I can't actually say that I remember seeing it.

Q- All right. Are you the D.T. Wigle at the bottom of page ...

A- Yes.

10 Q- That's referred to there?

A- Yes.

Q- And could you look at the appendix to see if that refreshes your memory?

A- I've looked through it quickly. It looks familiar, but
15 -- and undoubtedly this is what we sent in.

THE COURT:

When you say "we" -- that's Mr. Collishaw?

A- The three (3) authors, Collishaw...

Q- The three (3) authors.

20 A- ...Tostowaryk, Wigle. I'm sure I saw this before it went in, but...

Me POTTER:

Q- But you don't remember, eh?

A- I literally don't remember.

25

... I'd like Your Lordship to read these responses.
They're pretty funny.

Me EVRAIRE:

Well...

Me CHERNIAK:

The one at page four (4) particularly.

5 Me EVRAIRE:

Well, I'm so much shocked at my friend's language.

That's editorializing, it's totally unnecessary on the record.

Me CHERNIAK:

10 Well, read page four (4).

Me EVRAIRE:

Well, I fail to see the humour. So I'll mark it, then, as AG number... vous êtes perdu, là?

LE GREFFIER:

15 Non, c'est pas ça. C'est parce que ça serait rendu à "E".

THE COURT:

Non non, on le marque carrément.

Me EVRAIRE:

20 AG, oui.

LE GREFFIER:

186.

Me EVRAIRE:

186, très bien.

25

32/0065

THE COURT:

Je vais juste marquer une note pour quand monsieur
Collishaw témoignera, on lui fera identifier.

Me EVRAIRE:

5 C'est ça.

Q- Dr. Wigle, you took cognizance of the comments by the
Canadian Medical Journal Association's reviewer about
the paper that was put in as RJR-162? You took
cognizance of those comments?

10 A- That's 159.

Q- No, 162, the C.M.A.J. You took cognizance of the
comments that were attached by the reviewer to that
letter?

A- Yes, these are the comments...

15 Q- Thank you.

A- ... that we reviewed earlier.

Q- And you also took cognizance of the comments by
reviewers "A" and "B", associated with the Canadian
Journal of Public Health which my friend put in this
20 morning as well?

A- Yes.

Q- All right. And was the article that you had prepared
prior to taking cognizance of those comments printed in
substantially the same form in RJR-159?

25 A- Yes, the major revision that I recall is the addition of

the confidence limits.

Q- Doctor, why is that the only substantive change that you made to the article before its publication?

A- The only other substantive change...

5 Q- I said: why is that the only substantive change that you made?

A- Well, there's two (2) reasons.

Q- Okay.

A- One is that we were asked -- one of the main substantive
10 revisions requested was -- or not revisions, but one of the main criticisms was the fact that we were using the Godley data from the sixties (60s) for an estimate in Canada in the eighties (80s), and at the time that we did this report, those were the best data available, in
15 our opinion.

Q- M'hm.

A- The other major criticism was the failure to adjust for confounding factors as alleged by two (2) of the reviewers, but in fact in method one (1), we did adjust
20 the -- in the Nutrition Canada study, the relative risk of smoking for confounders. So, in fact, the criticism by the referee would seem to reflect the failure to appreciate what we did in method one (1).

Q- And why did you make no other changes?

25 A- Well, apart from correcting typographical errors, there

were no other changes that were necessary.

Q- Thank you. Those are my questions.

THE COURT:

Monsieur le greffier, l'avez-vous noté, ça?

5 LE GREFFIER:

Non, pas encore.

THE COURT:

So tomorrow is Dr. ...

Me EVRAIRE:

10 Kozlowski first, and then Dr. Ferrence.

THE COURT:

Ah, Kozlowski first?

Me EVRAIRE:

Just to complete the cross-examination and then Dr.

15 Ferrence.

THE COURT:

And that's Mr. Irving or yourself that's doing...

Me CHERNIAK:

No, it'll be Mr. Irving continuing.

20 Me EVRAIRE:

Just to assist Your Lordship, Mr. Irving has told me
that he will be about half a day with Dr. Kozlowski and
about an hour with Dr. Ferrence, just to give you a
sense of time.

25

Me CHERNIAK:

Yes, it'll be Mr. Irving. I may well be here for part of the day, but Mr. Irving will be conducting the cross-examination.

5 THE COURT:

Oh, I don't mind you being here, that's not the point. Because I wanted to know how much time we needed to finish Mr. Kozlowski.

Me CHERNIAK:

10 Oh, I see. I'm not sure...

THE COURT:

I have to tell you everything.

Me CHERNIAK:

Yes.

15 THE COURT:

Okay, thank you, Doctor. We can free the witness?

Me EVRAIRE:

Yes.

THE COURT:

20 You're free. Tomorrow at ten (10:00).

ADJOURNMENT